U.S. patent application number 13/563996 was filed with the patent office on 2012-11-29 for treatment methods using pharmaceutical solid state forms.
This patent application is currently assigned to Harbor Therapeutics, Inc.. Invention is credited to Mark Andres, Igor Ivanisevic, Kyle Stephens, Steven K. White, Brenton Skylar Wolfe.
Application Number | 20120302537 13/563996 |
Document ID | / |
Family ID | 41136126 |
Filed Date | 2012-11-29 |
United States Patent
Application |
20120302537 |
Kind Code |
A1 |
White; Steven K. ; et
al. |
November 29, 2012 |
TREATMENT METHODS USING PHARMACEUTICAL SOLID STATE FORMS
Abstract
The invention provides and describes solid state
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
including amorphous and crystalline forms and specific polymorphic
forms thereof. Anhydrates and solvates of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
include Form I anhydrate and Form IV and Form V solvates. The
invention further relates to solid and suspension formulations
containing
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in a
described solid state form and use of the formulations to treat
hyperglycemic conditions, such as type 2 diabetes and metabolic
syndrome, and autoimmune conditions, such as rheumatoid arthritis,
ulcerative colitis and type 1 diabetes, among other inflammation
related conditions in subjects or human patients. The invention
also relates to methods to make liquid formulations from solid
state forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
uses of such formulations in treating the described conditions.
Inventors: |
White; Steven K.; (San
Diego, CA) ; Ivanisevic; Igor; (West Lafayette,
IN) ; Stephens; Kyle; (West Lafayette, IN) ;
Andres; Mark; (West Lafayette, IN) ; Wolfe; Brenton
Skylar; (West Lafayette, IN) |
Assignee: |
Harbor Therapeutics, Inc.
San Diego
CA
|
Family ID: |
41136126 |
Appl. No.: |
13/563996 |
Filed: |
August 1, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12418559 |
Apr 3, 2009 |
8252947 |
|
|
13563996 |
|
|
|
|
61042240 |
Apr 3, 2008 |
|
|
|
Current U.S.
Class: |
514/182 |
Current CPC
Class: |
A61P 1/00 20180101; A61P
3/06 20180101; C07B 2200/13 20130101; A61P 37/00 20180101; A61P
37/02 20180101; A61P 37/06 20180101; A61P 3/10 20180101; A61P 9/10
20180101; A61P 9/00 20180101; A61P 3/00 20180101; A61P 3/04
20180101; C07J 5/00 20130101; A61P 25/16 20180101; A61P 19/02
20180101; C07J 7/0005 20130101; A61P 25/28 20180101; A61P 29/00
20180101; A61P 17/02 20180101; C07J 1/00 20130101; A61K 31/57
20130101; A61P 25/00 20180101; A61P 27/02 20180101; A61P 7/04
20180101; A61P 1/04 20180101 |
Class at
Publication: |
514/182 |
International
Class: |
A61K 31/57 20060101
A61K031/57; A61P 3/00 20060101 A61P003/00; A61P 3/10 20060101
A61P003/10; A61P 3/04 20060101 A61P003/04; A61P 3/06 20060101
A61P003/06; A61P 25/28 20060101 A61P025/28; A61P 25/16 20060101
A61P025/16; A61P 25/00 20060101 A61P025/00; A61P 27/02 20060101
A61P027/02; A61P 9/10 20060101 A61P009/10; A61P 7/04 20060101
A61P007/04; A61P 37/00 20060101 A61P037/00; A61P 1/00 20060101
A61P001/00; A61P 1/04 20060101 A61P001/04; A61P 29/00 20060101
A61P029/00 |
Claims
1. A method to treat an inflammation condition or a metabolic
disorder in a subject comprising administering to the subject an
effective amount of crystalline
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol.
2. The method of claim 1 wherein the crystalline
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form I
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol.
3. The method of claim 2 wherein the metabolic disorder is type 2
diabetes, hyperglycemia, obesity or hypercholesterolemia.
4. The method of claim 2 wherein the inflammation condition is a
disease or condition associated with neuroinflammation.
5. The method of claim 4 wherein the disease or condition
associated with neuroinflammation is Alzheimer's disease,
Parkinson's disease, amyotrophic lateral sclerosis and age-related
macular degeneration.
6. The method of claim 2 wherein the inflammation condition is
associated with ischemia, hemorrhage or a trauma.
7. The method of claim 6 wherein the inflammation condition
associated with ischemia, hemorrhage or a trauma is a myocardial
infarction or a stroke.
8. The method of claim 2 wherein the inflammation condition is an
autoimmune disease.
9. The method of claim 8 wherein the autoimmune disease is type 1
diabetes, multiple sclerosis or rheumatoid arthritis.
10. The method of claim 2 wherein the inflammation condition is an
inflammatory bowel disease.
11. The method of claim 10 wherein the inflammatory bowel disease
is ulcerative colitis or Crohn's disease.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This non-provisional U.S. patent application is a divisional
application of and claims priority to pending U.S. non-provisional
application serial No. 12/418,559 filed on Apr. 3, 2009, which
claims the benefit of U.S. provisional application Ser. No.
61/042,240 filed Apr. 3, 2008, now abandoned, both of which are
incorporated herein by reference in their entireties.
FIELD OF THE INVENTION
[0002] The invention relates to solid state forms of
17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,
16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17 S-triol
and methods for preparation of these solid state forms.
[0003] The invention further relates to solid formulations
comprising the solid state forms and to methods for using the solid
state forms, including the polymorph forms and pseudopolymorph
forms, in preparing solid and liquid formulations. The invention
further relates to methods for using the solid state forms for the
treatment of conditions related to hyperglycemia and autoimmunity.
Unit dosage forms for the solid and liquid formulations are also
included.
BACKGROUND OF THE INVENTION
[0004] The ability of a substance to exist in more than one
crystalline form is generally referred to as polymorphism and these
different crystalline forms are usually named "polymorphs" and may
be referred to by certain analytical properties such their X-ray
powder diffraction (XRPD) patterns. In general, polymorphism
reflects the ability of a molecule to change its conformation or to
form different intermolecular and intramolecular interactions. This
can result in different atom arrangements that are reflected in the
crystal lattices of different polymorphs. However, polymorphism is
not a universal feature of solids, since some molecules can exist
in one or more crystal forms while other molecules cannot.
Therefore, the existence or extent of polymorphism for a given
compound is unpredictable.
[0005] The different polymorphs of a substance posses different
crystal lattice energies and thus each polymorph typically shows
one or more different physical properties in the solid state, such
as density, melting point, color, stability, dissolution rate,
flowability, compatibility with milling, granulation and compacting
and/or uniformity of distribution [See, e.g., P. DiMartino, et al.,
J. Thermal Anal. 48:447-458 (1997)]. The capacity of any given
compound to occur in one or more crystalline forms (i.e.
polymorphs) is unpredictable as are the physical properties of any
single crystalline form. The physical properties of a polymorphic
form may affect its suitability in pharmaceutical formulations. For
example, those properties can affect positively or negatively the
stability, dissolution and bioavailability of a solid-state
formulation, which subsequently affects suitability or efficacy of
such formulations in treating disease.
[0006] An individual polymorph having one or more desirable
properties can be suitable for the development of a pharmaceutical
formulation having desired property(ies). Existence of a compound
with a polymorphic form(s) having undesirable properties can impede
or prevent development of the polymorphic form as a pharmaceutical
agent.
[0007] In the case of a chemical substance that exists in more than
one polymorphic form, the less thermodynamically stable forms can
occasionally convert to the more thermodynamically stable form at a
given temperature after a sufficient period of time. When this
transformation is rapid, such a thermodynamically unstable form is
referred to as a "metastable" form. In some instances, a metastable
form may exhibit sufficient chemical and physical stability under
normal storage conditions to permit its use in a commercial form.
Likewise, the amorphous form of an active pharmaceutical ingredient
may have different solubility in comparison to a given crystalline
material due to reduction of crystal lattice forces in the
amorphous material that must be overcome to effect dissolution in
aqueous or non-aqueous liquids.
SUMMARY OF THE INVENTION
[0008] In a principal embodiment, the invention provides new solid
state forms of 17-Ethynyl-10R,13S-dimethyl
2,3,4,7,8R,9S,10,11,12,13,14S,15,
16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol,
which is represented by Formula I. This compound is suitable for
treating a condition related to inflammation, hyperglycemia,
autoimmunity and related conditions such as diabetes and ulcerative
colitis.
##STR00001##
[0009] The compound of Formula I (hereafter also referred to as
Compound 1 or
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol) has
been prepared in amorphous and crystalline forms, and in
particular, crystalline forms referred herein as Form I, Form II,
Form III or Form IV.
[0010] Conditions related to hyperglycemia include hyperglycemia,
insulin resistance, Type 2 diabetes (including forms with (1)
predominant or profound insulin resistance, (2) predominant insulin
deficiency and some insulin resistance and (3) forms intermediate
between these), obesity and hyperlipidemia conditions such as
hypertriglyceridemia and hypercholesterolemia. The formulations
comprising a solid state form of Compound 1, including Crystalline
form I essentially free of amorphous Compound 1, amorphous Compound
1 essentially free of crystalline Compound 1 and a mixture of
crystalline and amorphous forms of Compound 1, are thus useful to
treat, prevent, ameliorate or slow the progression of Type 2
diabetes or other hyperglycemia conditions, in a subject such as a
human or a mammal.
[0011] Conditions related to autoimmunity include Type 1 diabetes
(including Immune-Mediated Diabetes Mellitus and Idiopathic
Diabetes Mellitus), multiple sclerosis, optic neuritis, Crohn's
disease (regional enteritis), ulcerative colitis, inflammatory
bowel disease, rheumatoid arthritis and Hashimotos' thyroiditis.
The formulations comprising a solid state form of Compound 1
including crystalline Form I, essentially free of other crystalline
and amorphous forms of Compound 1, and a mixture of crystalline and
amorphous forms of Compound 1 are thus useful to treat, prevent,
ameliorate or slow the progression of arthritis, ulcerative
colitis, multiple sclerosis, optic neuritis or other autoimmune
condition, in a subject such as a human or a mammal.
[0012] In diabetes, the formulations described herein are useful to
(1) enhance .beta.-cell function in the islets of Langerhans (e.g.,
increase insulin secretion), (2) reduce the rate of islet cell
damage, (3) increase insulin receptor levels or activity to
increase cell sensitivity to insulin and/or (4) modulate
glucocorticoid receptor activity to decrease insulin resistance in
cells that are insulin resistant.
[0013] One embodiment of the invention is directed to a particular
crystalline form of Compound 1 (e.g., crystalline Form I)
substantially free or essentially free of other crystalline or
amorphous forms of Compound 1.
[0014] In certain embodiments, the present invention is directed to
a particular polymorph form (e.g., crystalline Form I or Form II)
or pseudopolymorph form (e.g., crystalline Form III or Form IV) of
Compound 1 that is substantially free or essentially free of other
polymorph, pseudopolymorph or crystalline forms of Compound 1.
[0015] Another embodiment of the invention is directed to amorphous
Compound I, typically wherein the amorphous material is
substantially free or essentially free of crystalline Compound
1.
[0016] In certain embodiments, the present invention provides
methods of making, isolating and/or characterizing the solid state
forms of the invention. Some of these embodiments are directed to
methods to prepare Compound 1 in crystalline form. Other such
embodiments are directed to methods to prepare Compound 1 in
amorphous form.
[0017] In some embodiments a solid state form of Compound 1 is
characterized or identified by methods comprising X-ray Powder
Diffraction (XRPD) and one or more thermal methods including
Differential Thermal Analysis (DTA), Differential Scanning
calorimetry (DSC), Modulated Differential Scanning calorimetry
(mDSC), Thermogravimetric Analysis (TGA),
Thermogravimetric-infrared (TG-IR) analysis and melting point
measurements.
[0018] In some embodiments a solid state form of Compound 1 is
characterized or identified by methods including XRPD and a
vibrational spectroscopy method such as Raman spectroscopy.
[0019] Other embodiments of the invention are directed to solid
formulations comprising a solid state form of Compound 1 and
methods for preparation of the solid formulation.
[0020] In certain embodiments, the present invention encompasses
the use of the solid state forms of the invention for preparing a
final drug product. Preferred drug products are generally prepared
using Form I, Form III or amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0021] Other embodiments of the invention are directed to
pharmaceutically acceptable formulations comprising a particular
crystalline form (e.g. crystalline Form I, Form II, Form III or
Form IV) of Compound 1 that is substantially free or essentially
free of other solid state forms, such as amorphous Compound 1 or
other crystalline forms of Compound 1, and methods for preparation
of the formulations with solid and liquid formulations comprising
Form I most preferred.
[0022] Still other embodiments of the invention are directed to
liquid formulations prepared by contacting or admixing at least one
solid state form of Compound 1 with a liquid excipient into which
Compound 1 has sufficient solubility, optionally in the presence of
another excipient, and methods for preparation of the liquid
formulation.
[0023] Other embodiments that are related to contacting or admixing
at least one solid state form of Compound 1 with a liquid excipient
are directed to solid formulations as suspension formulation
wherein at least some amount of Compound 1 is present as particles
in the formulation. These suspension formulations are made using a
solid state form described herein.
[0024] Yet another embodiment of the invention is directed to
methods for treating a condition related to hyperglycemia and
autoimmunity in a subject with a solid formulation comprising a
solid state form of Compound 1 such as amorphous or a crystalline
form of Compound 1.
[0025] Yet another embodiment of the invention is directed to
methods for treating a condition related to hyperglycemia, such
Type 2 diabetes, in a subject with a solid formulation comprising a
particular crystalline form (e.g. crystalline Form I, Form II, Form
III or Form IV) of Compound 1 that is substantially free of other
solid state forms, such as amorphous and other crystalline forms of
Compound 1.
[0026] Another embodiment of the invention is directed to methods
for treating a condition related to autoimmunity, such as Type 1
diabetes, rheumatoid arthritis or Hashimotos' thyroiditis and an
inflammatory bowel disease such as Crohn's disease and ulcerative
colitis, in a subject with a solid formulation comprising a solid
state form of Compound 1, such as amorphous or a crystalline form
of Compound 1. In these embodiments crystalline Form I is
preferred.
[0027] Invention embodiments also include the use or Compound 1 in
amorphous or crystalline form for the preparation of a medicament
for the treatment or prophylaxis of a condition related to
hyperglycemia or autoimmunity.
[0028] Still other embodiments are directed to methods for
preparing liquid formulations using a solid state form of Compound
1 and uses of such formulations for treating a condition related to
hyperglycemia or autoimmunity.
[0029] Other embodiments and advantages of the present invention
are as described elsewhere in the specification including the
numbered embodiments and the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] FIG. 1 is a low resolution XRPD pattern of Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
prepared by bulk recrystallization.
[0031] FIG. 2 is a high resolution XRPD pattern of Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
after bulk micronization.
[0032] FIG. 3 is a low resolution XRPD of crystalline material from
an alternate preparation of Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0033] FIG. 4 provides differential scanning calorimetry and
thermogravimetric analysis thermograms of a sample containing
crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0034] FIG. 5 is a Raman spectroscopy spectrum with expanded region
for a sample containing crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0035] FIG. 6 are microscope photographs of crystals of crystalline
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
under 10.times. magnification.
[0036] FIG. 7 is a low resolution XRPD pattern of a sample
containing crystalline Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0037] FIG. 8 shows differential scanning calorimetry and
thermogravimetric thermograms of a sample containing crystalline
Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0038] FIG. 9 is a comparison of an experimentally derived XRPD
pattern for crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol with
allowed reflections from an indexing solution.
[0039] FIG. 10 is a comparison of an experimentally derived XRPD
pattern for crystalline Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol with
allowed reflections from an indexing solution.
[0040] FIG. 11 is a low resolution XRPD of a sample containing
crystalline Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0041] FIG. 12 are differential scanning calorimetry and
thermogravimetric analysis thermograms of a sample containing
crystalline Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0042] FIG. 13 is a Raman spectrum with expanded region for a
sample containing crystalline Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0043] FIG. 14 is a low resolution XRPD pattern of a sample
containing crystalline Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0044] FIG. 15 are differential scanning calorimetry and
thermogravimetric analysis thermograms of a sample containing
crystalline Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0045] FIG. 16 is a Raman spectrum with expanded region for a
sample containing crystalline Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0046] FIG. 17 is a low resolution XRPD pattern of a sample
containing amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0047] FIG. 18 provides differential scanning calorimetry and
thermogravimetric analysis thermograms of a sample containing
amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0048] FIG. 19 is a Raman spectrum with expanded region for a
sample containing amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
DETAILED DESCRIPTION
[0049] Definitions. As used herein or otherwise stated or implied
by context, terms that are defined herein have the meanings that
are specified. The descriptions of embodiments and examples that
are described illustrate the invention and they are not intended to
limit it in any way. Unless otherwise contraindicated or implied,
e.g., by mutually exclusive elements or options, in the
descriptions or throughout this specification, the terms "a" and
"an" mean one or more and the term "or" means and/or.
[0050] Unless specified otherwise explicitly or by context,
percentage amounts are expressed as % by weight (w/w). Thus, a
solid-dosage formulation containing at least about 2% Compound 1 is
a solid-dosage formulation or suspension containing at least about
2% w/w Compound 1. Solid Compound 1 containing 0.1% water means
0.1% w/w water is associated with the solid.
[0051] "About" and "approximately," when used in connection with a
numeric value or range of values which is provided to describe a
particular solid form, e.g., a specific temperature or temperature
range, such as, for example, that describing a melting,
dehydration, desolvation or glass transition; a mass change, such
as, for example, a mass change as a function of temperature or
humidity; a solvent or water content, in terms of, for example,
mass or a percentage; or a peak position, such as, for example, in
analysis by IR or Raman spectroscopy or XRPD; indicate that the
value or range of values may deviate to an extent deemed reasonable
to one of ordinary skill in the art while still describing the
particular solid state form. Specifically, the terms "about" and
"approximately," when used in this context, indicate that the
numeric value or range of values may vary by 20%, 10%, 9%, 8%, 7%,
6%, 5%, 4%, 3%, 2%, 10% 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%,
0.2%, 0.1% or 0.01% of the recited value or range of values while
still describing the particular composition or solid state
form.
[0052] "Solid State" as used herein refers to a physical state of a
compound or composition comprising the compound, such as
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
(i.e., Compound 1); wherein at least about 2-10% of the mass of the
compound that is present exists as a solid. Typically, the majority
of the mass of Compound 1 will be in solid state form. More
typically, between at least about 80-90% of the mass of Compound 1
is in solid form. Solid state forms include crystalline, disordered
crystalline, polycrystalline, microcrystalline, nanocrystalline,
partially crystalline, amorphous and semisolid forms or mixtures
thereof, optionally with non-solid or non-crystalline Compound 1.
Solid state forms of Compound 1 further include polymorphs,
pseudopolymorphs, hydrates, solvates, dehydrated hydrates and
desolvated solvates and mixtures thereof, optionally with non-solid
or non-crystalline Compound 1. Thus, solid state forms of Compound
1 will include a single polymorph form of Compound 1, a single
pseudo-polymorph form of Compound 1, a mixture of two or more,
typically two or three, polymorph or pseudo-polymorph forms of
Compound 1 or a combination of any one of these solid state forms,
optionally with non-solid or non-crystalline Compound 1, provided
that at least about 2-10% of the mass of Compound 1 is in solid
form.
[0053] The term "crystalline" and related terms used herein, when
used to describe a substance, component or product, means that the
substance, component or product is crystalline as determined by
visual inspection or usually with a suitable method, typically an
X-ray diffraction method such as X-ray powder diffraction [See,
e.g., Remington's Pharmaceutical Sciences, 18.sup.th ed., Mack
Publishing, Easton Pa., p 173 (1990); The United States
Pharmacopeia, 23.sup.rd ed., pp. 1843-1844 (1995)].
[0054] The term "crystalline forms" and related terms herein refers
to the various crystalline modifications of a given substance,
including, but not limited to, polymorphs, solvates, hydrates,
mixed solvates, co-crystals and other molecular complexes. A
crystalline form may also be a mixture various crystalline
modifications of a given substance such as a combination of
pseudopolymorph or polymorph forms, a combination of one or more
polymorph forms with one or more pseudopolymorph or a combination
of such forms with amorphous or non-solid state forms of the
substance. Typical combinations are of two or more polymorph or
pseudo polymorph forms, such a mixture of a polymorph form with a
pseudopolymorph form or a mixture of a polymorph or pseudopolymorph
form with amorphous material. Typically crystalline forms are
typically distinguishable from each other by their XRPD patterns.
Solid state forms having different crystal morphologies but
essentially identical XRPD patterns are considered to be different
crystalline forms, since different morphologies can exhibit
different properties related to physical shape. Properties related
to physical shape include dissolution rate, stability,
hygroscopicity, mechanical properties such hardness, tensile
strength, compatibility (tableting) and those related to handling,
e.g., flow, filtering, blending and other physical or
pharmaceutical properties as described herein for different
polymorphs.
[0055] "Polymorph" as used herein refers to a defined crystalline
form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
(i.e., Compound 1). Polymorphs typically differ in their physical
properties due to the order of the molecules in the lattice of the
polymorph. Thus, polymorphs may exhibit one or more differences in
physical or pharmaceutical properties including hygroscopicity,
solubility, intrinsic dissolution rate, solid state reaction rates
(i.e., chemical stability of a pharmaceutical ingredient as the
drug substance or drug product), crystalline stability (i.e.
tendency to transition to a more thermodynamically stable
crystalline form), surface free energy, interfacial tension,
mechanical strength (e.g., hardness, brittleness, plastic
deformation, docility, malleability, etc.), tensile strength,
compactability (i.e., tableting) and processability (e.g.,
handling, flow, blending, etc.). Differences in physical and
mechanical properties of polymorphic forms of a drug substance may
also affect scale-up and transfer from laboratory procedures though
pilot plant and then to full production.
[0056] Polymorphs existing as hydrates, solvates or mixed solvates
are generally referred to as pseudopolymorphs and represent
different polymorphic or solid state forms in view of an
isostructural polymorph form that is anhydrous or not a solvate.
Pseudopolymorphs that differ in solvate identity or stoichiometry
are also considered different polymorphic or solid state forms in
view of each other. For example, Compound 1 existing as a solvate
(e.g., crystalline Form III) is a different solid state form in
view of another solvate (e.g., crystalline Form IV) or an anhydrate
(e.g., crystalline Form I). Stability profiles of hydrates and
solvates at various temperatures and/or at different vapor
pressures of water (e.g., relative humidity) or organic solvents
will sometimes differ from those of the isostructural anhydrate or
desolvate. Such differences may influence formulation, processing
or stability of an active pharmaceutical ingredient (e.g., Compound
1), either as the drug substance in a drug product under various
storage conditions.
[0057] Thus, different crystalline or polymorphic forms may have
different physical properties such as, for example, melting
temperatures, heats of fusion, solubilities, and/or vibrational
spectra as a result of the arrangement or conformation of the
molecules in the crystal lattice (see, e.g., Byrn, S. R., Pfeiffer,
R. R., and Stowell, J. G. (1999) Solid-State Chemistry of Drugs,
2.sup.nd ed., SSCI, Inc.: West Lafayette, Ind.). The differences in
physical properties exhibited by polymorphs and pseudopolymorphs
may affect pharmaceutical parameters such as storage stability,
compressibility and density (important in formulation and product
manufacturing), and dissolution rate, which can be an important
factor in bioavailability. Differences in stability may result from
changes in chemical reactivity (e.g., differential oxidation, such
that a dosage form discolors more rapidly when comprised of one
polymorph or pseudopolymorph than when comprised of another
polymorphic form) or mechanical changes (e.g., tablets crumble on
storage as a kinetically favored polymorph converts to
thermodynamically more stable polymorph) or both (e.g., tablets of
one polymorph are more susceptible to breakdown at high humidity).
As a result of kinetic solubility/dissolution rate differences, in
the extreme case, some polymorphic transitions may result in lack
of potency or, at the other extreme, toxicity. In addition, the
physical properties of the crystal may be important in processing,
e.g., one polymorph might be more likely to form solvates or
hydrates that may be difficult to filter or wash free of impurities
due to, for example, by differences in crystal morphology and/or
particle size distribution.
[0058] Typically, crystalline forms are distinguished from each
other by one or more physical or analytical properties such as rate
of dissolution, Infrared and Raman spectroscopy, X-ray diffraction
techniques such as single crystal and powder diffraction
techniques, solid state-NMR (SS-NMR), thermal techniques such as
melting point, differential thermal analysis (DTA), differential
scanning calorimetry (DSC), thermal gravimetric analysis (TGA) and
other methods as disclosed elsewhere in the specification.
Additional methods to characterize or distinguish one
pseudopolymorph from another polymorphic form, include elemental
analysis, Karl-Fisher titration, dynamic vapor sorption analysis,
thermogravimetric-infrared spectroscopic analysis (TG-IR), residual
solvent gas chromatography and .sup.1H-NMR.
[0059] The term "isostructural crystalline form," as used herein,
refers to a crystal form of a substance that has a common
structural similarity with another crystalline form, including
approximately similar interplanar spacing in the crystal lattice.
Thus, isostructural crystalline forms will have similar molecular
packing motifs, but differing unit cell parameters (a symmetry
translation). Due to their common structural similarity,
isostructural crystalline forms typically have similar, but not
necessarily identical, X-ray powder diffraction patterns. An
isostructural crystalline form may be based upon a substance that
is a neutral molecule or a molecular complex. The isostructural
crystalline form may be a solvate, including a hydrate, or a
desolvated solvate crystalline form of the substance. Isostructural
forms that are solvates of a polymorph are sometimes referred to as
pseudopolymorphic to the unsolvated polymorph. A solvated
crystalline form typically contains one or more solvents, including
water, in the crystal lattice, that may be the solvent or solvents
of crystallization used in preparing the crystalline form.
[0060] "Amorphous", as used herein, refers to a solid state form of
a compound (e.g., Compound 1) wherein in the three dimensional
structure positions of the molecules relative to one another are
essentially random, [for example, see Hancock et al.
"Characteristics and significance of the amorphous state in
pharmaceutical systems" J. Pharm. Sci. Vol. 86, pp. 1-12 (1997)].
As a result, amorphous material will have only liquid-like short
range order, and, when examined by X-ray diffraction, will
generally produce broad, diffuse scattering will result in peak
intensity sometimes centered on one or more amorphous halos. Thus,
XRPD analysis of amorphous material will provide a 2-theta pattern
with one or more broad bands with no distinctive peaks.
[0061] Amorphous Compound 1 may sometimes be characterized by its
glass transition temperature (T.sub.g), which defines a pseudo
second order phase transition in which a supercooled melt of
Compound 1 yields, on cooling, a glassy structure with properties
similar to those of crystalline Compound 1. However, since T.sub.g
is a kinetic parameter, its value will be dependent on the melt
cooling rate and the measurement conditions used for its
determination (e.g., the slower the melt cooling rate, the lower
T.sub.g will be). Furthermore, T.sub.g of an amorphous sample, such
as amorphous Compound 1 will be highly dependent on the amount of
water present. For example, a 1% increase in water content may
lower T.sub.g by about 10.degree. C. or more. The glass transition
temperature for a sample of amorphous Compound 1 may be obtained by
differential scanning calorimetry (DSC), which will exhibit a heat
capacity change having a second order endothermic transition that
appears as a step transition. The inflection point of this
transition provides T.sub.g.
[0062] "Formulation" or "pharmaceutically acceptable formulation"
as used herein refers to a composition comprising
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
(i.e., Compound 1), present in a solid state form in addition to
one or more pharmaceutically acceptable excipients. Formulations
include compositions prepared from a solid state form of Compound
1, wherein the composition is suitable for administration to a
human. The formulation may be comprised of, or be prepared from,
one, two or more crystalline forms of Compound 1, e.g. a single
polymorph or pseudopolymorph form of Compound 1, a mixture of two
polymorph forms of Compound 1 or a mixture of a polymorph form of
Compound 1 and a pseudopolymorph form of Compound 1. The
formulation may be comprised of, or be prepared from amorphous
Compound 1 or a mixture of a polymorph or pseudopolymorph form of
Compound 1 and amorphous Compound 1. Typically, the formulations
will be comprised of, or prepared from, a single crystalline form
of Compound 1 (e.g., crystalline Form I, Form II, Form III or Form
IV), amorphous Compound 1 or, less preferably, a mixture of a
single polymorph or pseudopolymorph form and amorphous Compound 1.
Preferred formulations contain Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0063] "Solid formulation" as used herein refers to a formulation
wherein Compound 1 is in solid state form in the presence of one or
more pharmaceutically acceptable excipients wherein the majority of
the mass amount of the solid state form of Compound 1 used in
preparation of the formulation remains in that solid state form for
at least about 6 months at ambient temperature, usually for at
least about 12 months or 24 months at ambient temperature, when
admixed with the excipients in proportions required for the solid
state formulation. Dosage units that are a solid formulation
include tablets, capsules, caplets, suspensions and other dosage
units typically associated with oral administration of an active
pharmaceutical ingredient in solid state form to a subject in need
thereof.
[0064] "Liquid formulation" as used herein refers to a formulation
wherein one or more solid state forms of Compound 1 has been
admixed or contacted with one or more excipients, wherein at least
one of the excipients is in liquid or non-solid state form (i.e. a
non-solid excipient), in proportions required for the liquid
formulation, such that a majority of the mass amount of Compound 1
is dissolved into the non-solid excipient. Dosage units containing
a liquid formulation include syrups, gels, ointments and other
dosage units typically associated with parenteral or enteral
administration of an active pharmaceutical ingredient to a subject
in need thereof in non-solid state form.
[0065] "Substantially free" as used herein refers to a compound
such as Compound 1 wherein more than about 60% by weight of the
compound is present as the given solid state form. For example, the
term crystalline Compound 1 "substantially free" of amorphous
material refers to a solid-state form of Compound 1 wherein more
than about 60% of Compound 1 is in one or more crystalline forms.
Such compositions preferably contain at least about 80%, more
preferably at least about 90%, of Compound 1 in one or more
crystalline forms with the remaining present as amorphous or
non-crystalline Compound 1. In another example, the term amorphous
Compound 1 "substantially free" of crystalline forms refers to a
solid-state form of Compound 1 wherein more than about 60% of
Compound 1 is amorphous. Such compositions typically contain at
least about 80%, preferably at least about 90%, more preferably at
least about 95%, of amorphous Compound 1, with the remaining
present as one or more crystalline forms of Compound 1. In yet
another example, the term Form I "substantially free" of other
crystalline forms refers to a solid-state composition wherein more
than about 60% of Compound 1 exists as a single crystalline form.
Such compositions typically contain at least about 80%, preferably
at least about 90%, more preferably at least about 95% Compound 1
as a single crystalline form. Preferred formulations contain at
least about 80%, preferably at least about 90% and more preferably
at least about 95% of Compound 1 as Form I, with the remaining
Compound 1 present as other crystalline forms or in amorphous form
or a combination thereof. Other preferred formulations contain at
least about 80%, preferably at least about 90% and more preferably
at least about 95% of Compound 1 in amorphous form with the
remaining Compound 1 present in one or more crystalline forms. Most
preferred formulations contain about 95-99% of Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol with
about 97%, about 98% or about 99% particularly preferred.
[0066] "Essentially free" as used herein refers to a component so
identified as not being present in an amount that is detectable
under typical conditions used for its detection or would adversely
affect the desired properties of a composition or formulation in
which the component may be found. For example, "essentially free of
liquid" means a composition or formulation in solid form that does
not contain water or solvent, in liquid form, in an amount that
would adversely affect the pharmaceutical acceptability of the
formulation or composition for use in a solid dosage form to be
administered to a subject in need thereof. A suspension is
considered a solid formulation and for such formulations liquid
excipient(s) comprising the suspension formulation are not included
within this definition. "Crystalline Form I essentially free of
amorphous Compound 1" refers to a specific crystalline form of
Compound 1 in which amorphous Compound 1 is not detected by XRPD
analysis. Typically, the detection limit for amorphous material
within crystalline material is about 10%.
[0067] "Substantially pure" as used herein refers to a solid state
form of Compound 1 that contain less than about 3% or less than
about 2% by weight total impurities, or more preferably less than
about 1% by weight water, and/or less than about 0.5% by weight
impurities such as decomposition or synthesis by-products or
residual organic solvent. Residual solvent does not include solvent
that is part of a solvate of a solid state form of Compound 1 (e.g.
a pseudopolymorph).
[0068] "Substantially identical" as used herein refers to measured
physical characteristics that are comparable in value or data
traces that are comparable in peak position and amplitude or
intensity within the scope of variations that are typically
associated with sample positioning or handling or the identity of
the instrument employed to acquire the traces or physical
characteristics or due to other variations or fluctuations normally
encountered within or between laboratory environments or analytical
instrumentation.
[0069] "Hydrate" as used here refers to a solid state form of
Compound 1 that contains water molecules as an integral part of the
solid state form and does not refer to water that is
non-specifically bound to the bulk compound. Hydrates of Compound 1
in a crystalline form can be isolated site hydrates or channel
hydrates. Hydrates can contain stoichiometric or nonstoichiometric
amounts of water molecules per Compound 1 molecule. Typically,
water will be present in a hydrate in the ratio of 0.25, 0.5, 1.0,
1.5 or 2.0 relative to Compound 1 on a mole basis.
[0070] "Solvate" as used here refers to a solid state form of
Compound 1 that contains solvent molecules that is combined in a
definite ratio to the molecules of the compound and is an integral
part of the solid state form and does not refer to solvent that is
non-specifically bound to bulk compound. When the solvent molecule
is water such solvates are referred to as hydrates.
[0071] "Inflammation condition" as used herein refers to a
condition that is characterized by the inappropriate or
pathological presence of inflammation or its associated pain or
fever. Inflammation may be present as a flare as for example in an
autoimmune disease such as multiple sclerosis. Inflammation may be
acute or chronic and present in conditions such as Type 2 diabetes,
Alzheimer's disease and metastatic cancer, e.g., metastatic
prostate or breast cancer.
[0072] Inflammation conditions include autoimmune conditions, such
as multiple sclerosis, a lupus condition, e.g., systemic lupus
erythematosus, an arthritis condition, e.g., rheumatoid arthritis,
and an inflammatory bowel condition, e.g. as ulcerative colitis or
Crohn's disease. Inflammation conditions also include metabolic
conditions, such as hyperglycemia conditions, diabetes, liver
cirrhosis conditions, e.g., nonalcoholic steatohepatitis (NASH),
fatty liver conditions, acute and chronic lung conditions, e.g.,
obstructive pulmonary disease (COPD), acute asthma, chronic asthma,
emphysema, acute bronchitis, allergic bronchitis, chronic
bronchitis and lung fibrosis.
[0073] "Metabolic condition" as used herein include conditions such
as type 1 diabetes, type 2 diabetes, obesity, metabolic syndrome,
insulin resistance, hyperglycemia, impaired glucose utilization or
tolerance, impaired or reduced insulin synthesis, a hyperlipidemia
condition, such as hyperlipidemia, hypercholesterolemia,
hypertriglyceridemia, elevated free fatty acids, or macrovascular
damage, such as arterial atherosclerosis, hypolipidemias or
vascular atherosclerosis. Hypercholesterolemia includes hyper-LDL
cholesterolemia or elevated LDL cholesterol. Hypolipidemias include
hypo-HDL cholesterolemia or low HDL cholesterol levels. Type 1
diabetes includes Immune-Mediated Diabetes Mellitus and Idiopathic
Diabetes Mellitus. Type 2 diabetes includes forms with predominant
or profound insulin resistance, predominant insulin deficiency and
some insulin resistance and forms intermediate between these.
[0074] Solid state forms of Compound 1 can also be used to treat
diseases or conditions associated with neuroinflammation such as
Alzheimer's disease, Parkinson's disease, amyotrophic lateral
sclerosis and age-related macular degeneration.
[0075] An "excipient", "carrier", "pharmaceutically acceptable
carrier" or similar terms mean one or more component(s) or
ingredient(s) that is acceptable in the sense of being compatible
with the other ingredients in compositions or formulations
comprising Compound 1 as the active pharmaceutical ingredient that
is in solid state form when admixed with the excipients. These
excipients usually are not overly deleterious to a subject to whom
the composition formulation is to be administered. Excipients
include one or more components typically used in the pharmaceutical
formulation arts, e.g., one, two or more of fillers, binders,
disintegrants, dispersants, preservatives, glidants, surfactants
and lubricants. Exemplary excipients include povidone,
crospovidone, corn starch, carboxymethyl cellulose, hydroxypropyl
methylcellulose, microcrystalline cellulose, gum arabic,
polysorbate 80, butylparaben, propylparaben, methylparaben, BHA,
EDTA, sodium lauryl sulfate, sodium chloride, potassium chloride,
titanium dioxide, magnesium stearate, castor oil, olive oil,
vegetable oil, buffering agents such as sodium hydroxide, monobasic
sodium phosphate, dibasic sodium phosphate, potassium hydroxide,
monobasic potassium phosphate, dibasic potassium phosphate,
tribasic potassium phosphate, potassium carbonate, potassium
bicarbonate, ammonium hydroxide, ammonium chloride, saccharides
such as mannitol, glucose, fructose, sucrose or lactose.
[0076] A "subject" means a human or an animal. Usually the animal
is a mammal or vertebrate such as a non-human primate dog or
rodent.
[0077] A "surface-active agent" (surfactant) means a substance,
which, at low concentrations, interacts between the surfaces of a
solid and fluid in which the solid is insoluble or sparingly
soluble. The fluid may be a liquid excipient present in a
suspension formulation comprising a solid state form of an active
pharmaceutical ingredient, such as a crystalline form of Compound
1, the liquid excipient and the surface active agent that acts to
improve suspendability. Alternatively, the surface active agent may
be present in an oral solid dosage form comprising a polymorph or
pseudopolymorph of Compound 1 (e.g., crystalline Form I, Form II,
Form III or Form IV), the amorphous form of Compound 1 or a mixture
thereof and the surface active agent, which acts to improve
dissolution rate of the active pharmaceutical ingredient in the
gastric fluid. Surface-active agents are amphipathic in structure
having both polar (hydrophilic) and non-polar (hydrophobic) regions
in the same molecule. Examples of surface active agents used in the
formulation arts are given in Corrigan, O. I.; Healy, A. M.
"Surfactants in Pharmaceutical Products and Systems" in
Encyclopedia of Pharmaceutical Technology 2.sup.nd ed. Taylor and
Francis, 2006, pp. 3583-3596.
[0078] A "suspension" generally refers to a solid state form of
Compound 1 that is present, usually as a finely divided (e.g.,
micronized) solid, in a liquid carrier (vehicle) at a time prior to
administration of the suspension. The suspension may be either
ready to use or a dry powder reconstituted as a suspension dosage
form just prior to use. Suspensions typically include a suspending
or flocculating agent, a wetting agent, if the suspending or
flocculating agent that is present does not already serve this
purpose, a buffering agent and a preservative. In a colloidal
suspension, the Compound 1 particles are typically less than about
1 .mu.m in size. In a coarse suspension, they are larger than about
1 .mu.m. The practical upper limit for individual suspendable
Compound 1 particles in coarse suspensions is about 50 .mu.m to 75
.mu.m although some proportion of particles up to 200 .mu.m may be
suitable dependent upon the syringeability of the suspension.
Design considerations for developing a suspension for oral or
parenteral administration are given in Akers, et al. J. Parenteral
Sci. Tech. 1987 Vol. 41, pp. 88-96; Nash, RA "Suspensions" in
Encyclopedia of Pharmaceutical Technology 2.sup.nd ed. Taylor and
Francis, 2006, pp 3597-3610 (which is hereby incorporated herein by
reference with specificity into the present application).
[0079] Characterization and Identification Methods for Solid State
Forms
[0080] Morphology
[0081] Crystal morphology refers to the symmetry in a crystal as
exhibited by its crystal faces due to the ordered internal
arrangement of atoms in the crystal structure. Crystal morphology
of a particular crystalline form is sometimes described by the
crystalline form's crystal system, namely, triclinic, monoclinic,
orthorhombic, tetragonal, hexagonal or isometric. More typically,
crystal morphology of crystals in a sample of crystalline material
refers to the physical appearance of the majority of the crystals
in the sample and is indicated by a shape descriptive label such as
blades, plates, tablets, needles, etc. Crystal morphology may be
determined by observation, for example by microscopic evaluation
under at about 2.times., 10.times., 40.times. or 100.times.
magnification using normal or polarized light.
[0082] X-ray Powder Diffraction
[0083] X-Ray powder diffraction (XRPD) is typically used to
characterize or identify crystalline compounds (see, e.g., U.S.
Pharmacopoeia, volume 23, 1995, method 941, pp. 1843-1845, U.S.P.
Pharmacopeia Convention, Inc., Rockville, Md.; Stout et al, X-Ray
Structure Determination; A Practical Guide, MacMillan Co., New
York, N.Y. 1968). When an X-ray beam interacts with a crystalline
form a diffraction pattern is typically produced characterized by
sequences of intensity maximums at positions that depend on lattice
features of the crystalline form. Thus, the positions and the
relative intensity of the XRPD lines are indicative of a particular
crystalline form that provide a "fingerprint" that is often
specific for a given crystalline form, although weak or very weak
diffraction peaks may not always appear in replicate diffraction
patterns obtained from successive batches of crystals. This is
particularly the case if other crystalline forms are present in the
sample in appreciable amounts, e.g., when a polymorph or
pseudopolymorph form has become partially hydrated, dehydrated,
desolvated or heated to give a significant amount of another
polymorph or pseudopolymorph form.
[0084] Furthermore, the relative intensities of bands, particularly
at low angle X-ray incidence values (low 2.theta.), may vary due to
preferred orientation effects arising from differences in, e.g.,
crystal habit, particle size and other conditions of measurement.
Thus, one typically looks to the relative positioning of the peaks
coupled with their amplitude. Broad XRPD peaks, which may consist
of two or more individual peaks located closely together, may be
produced by amorphous components, disordered crystalline forms or
parasitic scatter from the main beam. Broad peaks for different
samples of the same solid state form are generally located within
about 0.3-1 degree 2.theta.. Sharp isolated XRPD peaks for
different samples of the same solid state form are usually found
for normal resolution data within about 0.1 2.theta. degrees or
occasionally within about .+-.0.2 2.theta. degrees on successive
XRPD analyses. Thus, when a sharp isolated XRPD peak at a given
position is identified as being located at, e.g., about 16.1 or
16.07 this means that the peak is at 16.1.+-.0.1 or 16.07.+-.0.1.
When a broad XRPD peak at a given position is identified as being
located at about a given degree 2.theta. value, this means that the
peak is at that degree 2.theta. value .+-.0.3.
[0085] An XRPD pattern may be described by "Prominent Peaks".
Prominent peaks are selected from observed peaks by identifying
preferably non-overlapping, low-angle peaks. A prominent peak will
have relative intensity of at least about 5% or more typically at
least about 10% or at least about 15% or at least about 20%
relative intensity in comparison to the most intense peak in the
X-ray diffraction pattern. Sometimes one or more peaks of intensity
lower than 5% may be considered prominent are used in addition with
one or more peaks that are more prominent (i.e. at least about 10%
or at least about 15% or at least about 20% relative intensity) in
order to describe an XRPD pattern for a crystalline form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0086] Under reproducible intra-lab conditions using the same
instrument and protocol to obtain the XRPD patterns, the
differences in XRPD peak locations and intensities obtained from
successive XRPD analyses on different samples of the same solid
state form having the same degree of crystallinity are due
primarily to differences in sample preparation or the purity of the
sample.
[0087] It is usually not necessary to rely on all peaks that one
observes in a purified polymorph or pseudopolymorph sample
disclosed herein, since even a single band may be diagnostic of a
given polymorph or pseudopolymorph form of Compound 1. Rather,
identification should typically focus on peak position and general
pattern, particularly on the selection of prominent peaks to
distinguish the various polymorph and pseudopolymorph forms
described herein. Typically, an individual polymorph or
pseudopolymorph form of Compound 1 is described by reference to the
2, 3 or 4 most intense peaks or to 2, 3 or 4 prominent peaks and
optionally by reference to one or two other physical or analytical
properties. Those properties include melting point, one or more
thermal transitions observed in differential thermal analysis (DTA)
or differential scanning calorimetry (DSC), percent weight loss in
TGA occurring within a defined range of temperature, one or more
absorption peaks observed in infrared or Raman spectroscopy and
intrinsic dissolution rate (DR). Standardized methods for obtaining
XRPD, DTA, DSC, DR, etc. data have been described for example in
U.S. Pharmacopoeia, volume 23, 1995, United States Pharmacopeial
Convention, Inc., Rockville, Md., pp 2292-2296 and 2359-2765
(incorporated herein by reference).
[0088] One method to identify a known polymorph or pseudopolymorph
form within a suspected solid state sample, such as a solid state
formulation comprising the known polymorph or pseudopolymorph form,
involves obtaining one or more XRPD patterns from sample(s)
containing the known polymorph or pseudopolymorph form, which are
then compared with the XRPD patterns of the suspected solid state
sample using, for example, a heuristic clustering analysis method
as described for example in US Pat. Appl. Publ. No. 2004/0103130
(incorporated herein by reference particularly at paragraphs
0067-0078 and paragraphs 0086-0115 inclusive). Heuristic clustering
analysis may also be used for quantitative analysis of samples
containing either mixed crystalline phases (e.g., mixture of two or
more polymorph forms) or mixed crystalline and disordered phases
(e.g. mixture of a polymorph and amorphous forms) as described for
example in US Pat. Appl. Publ. No. 2004/0103130 (incorporated
herein by reference, particularly at paragraphs 0116-0130
inclusive).
[0089] Comparisons of atomic pairwise distribution functions (PDFs)
derived from XRPD patterns may also be used to identify a known
polymorph or pseudopolymorph in a suspected solid state sample,
such as a solid state formulation comprising the known polymorph or
pseudopolymorph form. If two crystalline forms are of the same
molecule with the same molecular packing, their PDFs will be
essentially the same. To determine if two PDFs derived from, for
example, a known polymorph form or pseudopolymorph form and a solid
state formulation suspected of containing these crystalline forms
are essentially identical, the PDFs are compared by, for example,
the method described in US Pat. Appl. Publ. No. 2007/0243620
(incorporated herein by reference).
[0090] If high resolution XRPD pattern(s) of an essentially pure
polymorph or pseudopolymorph may be obtained, then unit cell
parameters (as described in the section on single crystal X-ray
analysis) may be determined for the crystalline form by an indexing
method as, for example, in US Pat. Appl. Publ. No. 2007/0270397
(incorporated herein by reference). For a pseudopolymorph, if an
isostructural crystalline form (i.e., a reference crystalline
form), such as an isostructural anhydrate, which may be derived
from dehydration and/or desolvation of the pseudopolymorph, may be
obtained, then comparison of the unit cell volume of the
isostructural crystalline form with the unit cell volume determined
from high resolution XRPD pattern(s) may allow determination of the
stoichiometry of the pseudopolymorph (i.e., number of water or
solvent molecules per molecule of Compound 1). In such
applications, the unit cell parameters for the reference
isostructural crystalline form may be obtained from single crystal
X-ray analysis or derived from indexing of high resolution XRPD
data for this reference form.
[0091] Indexing may also be used to determine if a solid state form
of Compound 1 contains a given crystalline form essentially free of
other crystalline forms. This may be done by comparing the allowed
reflections of the unit cell determined by an aforementioned
indexing method with the peaks of the experimentally derived XRPD
pattern taking into account those peaks that would be absent due to
destructive interference. The presence of one or more prominent
peaks in the experimental XRPD not allowed by the indexing solution
indicates the presence of one or more other crystalline forms of
Compound 1.
[0092] Vibrational Spectroscopy
[0093] Diagnostic techniques that one can optionally use to
characterize crystalline forms of Compound 1, such as a polymorph
or pseudopolymorph form, include vibrational spectroscopy
techniques such as IR and Raman, which measure the effect of
incident energy on a solid state sample due to the presence of
particular chemical bonds within molecules of the sample that
vibrate in response to the incident energy. Because polymorphs and
pseudopolymorph form may possess different IR and Raman
characteristics from each other, IR and Raman spectrum provide
complementary information and either may provide a fingerprint for
identification of a particular polymorph. [see, Anderton, C. Eur.
Pharm. Rev., Vol. 9, pp. 68-74 (2004)].
[0094] Raman is capable of determining polymorph or pseudopolymorph
identity and/or quantification in a complex matrix, such as a
tablet formulation, and of distinguishing between amorphous and
crystalline forms or differentiating between multiple polymorphic
and pseudo polymorphic forms of Compound 1 [for example, see
Pratiwia, D., et al. "Quantitative analysis of polymorphic mixtures
of ranitidine hydrochloride by Raman spectroscopy and principal
components analysis" Eur. J. Pharm. Biopharm. Vol. 54, No. 3, pp.
337-341 (2002)]. For formulations containing a mixture of
crystalline forms, recognition of about 10% polymorphic or
pseudopolymorphic impurity of Compound 1 (representing an absolute
detection limit of about 0.05% w/w), is sometimes possible.
[0095] For determining polymorph or pseudopolymorph identity or
quantification of a crystalline form of Compound 1 within a complex
matrix such as a solid formulation using the above vibrational
spectroscopy methods, the technique of attenuated total reflectance
(ATF) is sometimes used (for an example see Salari, H., et al.
"Application of attenuated total reflectance FTIR spectroscopy to
the analysis of mixtures of pharmaceutical polymorphs" Intl. J.
Pharm., Vol. 163, No. 1, pp. 157-166 (1998)].
[0096] Another technique for identification or quantification of
crystalline material, such as a crystalline form of Compound 1 is
Diffuse Reflectance Infrared Fourier Transform Spectroscopy
(DRIFTS) (for an example see Tantishaiyakul, V., et al. "Use of
DRIFTS and PLS for the Determination of Polymorphs of Piroxicam
alone and in combination with pharmaceutical excipients: A
Technical Note" AAPS PharmSciTech, Vol. 9, No. 1, pp. 95-99
(2008)].
[0097] In yet another technique, near-infrared (NIR) spectroscopy
may also be used in identification or quantitative analysis of a
crystalline form, such as a polymorphs or pseudo polymorph form
(e.g., hydrate) of Compound 1 in a mixture of solid state forms or
identification of a polymorph or pseudopolymorph form in a solid
formulation such as a tablet containing the polymorph or
pseudopolymorph form of Compound 1.
[0098] Overlap of IR or Raman bands from different crystalline
forms of Compound 1 examined by various vibration spectroscopy
methods may sometimes occur so that identification or
quantification requires deconvolution methods to extract
information for each individual component. Such deconvolution
methods include partial least squares regression, principle
component analysis or other methodologies [for examples, see Reich,
G. "Near-infrared spectroscopy and imaging: Basic principles and
pharmaceutical applications" Adv. Drug Deliv. Rev., Vol. 57, pp.
1109-43 (2005)].
[0099] Solid State Nuclear Magnetic Resonance (SS-NMR)
[0100] Diagnostic techniques that one can optionally use to
characterize polymorphs of Compound 1 include solid state NMR
techniques [for examples see Tishmack, P.A., et al. "Solid-State
Nuclear Magnetic Resonance Spectroscopy: Pharmaceutical
Applications," J. Pharm. Sci. Vol. 92, No. 3, pp. 441-474 (2003)].
These techniques offer the advantage of being nondestructive and
noninvasive. SS-NMR spectroscopy is sometimes suitable for testing
drug formulations, such as those comprising Compound 1, because the
NMR resonances for most pharmaceutical excipients occur in a narrow
range of the NMR spectrum.
[0101] SS-NMR may also be applied to analyzing solid formulations
comprising Compound 1 and thus may be useful for detecting
different solid state forms of Compound 1 in the presence of
excipients. For detecting amorphous Compound 1 in a solid state
sample of Compound 1 the detection limit for SS-NMR is expected to
be about 10-20%, depending on the relative location of the peaks
form amorphous and crystalline forms in their spectra, because
amorphous peaks generally are very broad. This is about the same
detection limit for XRP D. In addition, because NMR spectroscopy is
inherently a quantitative technique (i.e., signal intensity is
relative to the number of nuclear sites at that specific resonance
frequency), SS-NMR spectroscopy may allow one to determine the
contribution of crystalline forms of Compound 1, or of crystalline
and amorphous Compound 1, in a mixture of such forms.
[0102] Thermal Analysis Procedures
[0103] Diagnostic techniques that one can optionally use to
characterize polymorphs of Compound 1 include differential thermal
analysis (DTA), differential scanning calorimetry (DSC),
thermo-gravimetric analysis (TGA) and melting point
measurements.
[0104] DTA and DSC measure thermal transition temperatures at which
a crystalline form absorbs or releases heat when its crystal
structure changes or it melts. TGA is used to measure thermal
stability and the fraction of volatile components of a sample by
monitoring the weight change as the sample is heated. If infrared
spectroscopy is conducted on the volatile components outgassed
during TGA analysis of a pseudopolymorph (TGA-IR), then the
molecular composition of the pseudopolymorph can be determined.
These techniques are thus useful for characterizing solid state
forms existing as solvates and/or hydrates.
[0105] DTA involves heating a test sample of a solid state form of
Compound 1 and an inert reference under identical conditions while
recording any temperature difference between the sample and
reference.
[0106] DSC measures the energy needed to establish a nearly zero
temperature difference between a sample and an inert reference as
they are subjected to identical heating regimes.
[0107] Thermal transition temperatures observed in DSC and DTA
typically occur within about 2.degree. C. or .+-.2.degree. C. on
successive analyses using a temperature scan rate of 10.degree.
C./min and may occur within about 1.degree. C. or .+-.1.degree. C.
depending on the temperature scan rate used (with slower scan rates
such as 5.degree. C./min or 1.degree. C./min sometimes providing
greater precision). When a sample of Compound 1 has a DSC or DTA
transition at a given value, it means that the DSC or DTA
transition will usually be within about 2.degree. C. or
.+-.2.degree. C. for that sample for a sharp transition such as an
sharp endotherm peak. For broad transitions, a temperature
transition refers to the center of the peak (for exothermic
transitions or valley (for endothermic transitions) of that
transition. For broad transitions, particularly those resulting
from dehydration or desolvation, successive analyses using a
temperature scan rate of 10.degree. C./min may occur within about
3.degree. C. or .+-.3.degree. C. or more for very broad
transitions. Different crystalline forms including polymorph or
pseudopolymorph forms may be identified, at least in part, based on
their different transition temperature profiles in their DSC or DTA
thermographs.
[0108] Thermal analysis is usually conducted at a temperature scan
rate of 10.degree. C./min. Lower scan rates such as 5.degree.
C./min or 1.degree. C./min may be used if overlap of temperature
transitions is suspected. Thus, a suspected transition due to a
change in polymorph form to a different, more stable polymorph
prior to complete melting of the sample may be discerned using a
slower scan rate. A transition during thermal analysis of a
kinetically formed polymorph to a thermodynamically more stable
polymorph prior to complete melting may be avoided using a faster
scan rate that does not allow time for the transition to occur.
[0109] Data Acquisition for Characterization and Identification
Methods
[0110] Data provided in various Figures, Tables and Examples were
obtained using the following methods and instrumentation.
[0111] X-Ray Powder Diffraction
[0112] XRPD patterns were obtained using one of the following
methods. A PANalytical X'Pert Pro diffractometer. An incident beam
of Cu K.alpha. radiation was produced using an Optix long,
fine-focus source. An elliptically graded multilayer mirror was
used to focus the Cu K.alpha. X-rays of the source through the
specimen and onto the detector. A beam-stop and a helium atmosphere
were used to minimize the background generated by air scattering.
Soller slits were used for the incident and diffracted beams to
minimize axial divergence. Prior to the analysis, a silicon
specimen (NIST SRM 640c) was analyzed to verify the Si 111 peak
position. Diffraction patterns were collected using a scanning
position-sensitive detector (X'Celerator) located 240 mm from the
specimen. Data were collected and analyzed using X'Pert Pro Data
Collector software (v. 2.2b). The specimen was sandwiched between 3
.mu.m thick films, analyzed in transmission geometry, and rotated
to optimize orientation statistics.
[0113] XRPD patterns were also collected using an Inel XRG-3000
diffractometer equipped with a curved position sensitive detector
with a 28 range of 120.degree.. An incident beam of Cu K.alpha.
radiation (40 kV, 30 mA) was used to collect data in real time at a
resolution of 0.03.degree. 2.theta. starting at about 4.degree.
2.theta.. The monochromator slit was set at 5 mm by 160 .mu.m.
Prior to the analysis, a silicon standard (NIST SRM 640c) was
analyzed to verify the Si 111 peak position. Diffraction radiation
was detected by a sodium iodide scintillation detector. Samples
were analyzed for 300 sec. Samples were prepared for analysis by
packing them into thin-walled glass capillaries. Each capillary was
mounted onto a goniometer head and rotated during data
acquisition.
[0114] XRPD patterns were also obtained on a Shimadzu WRD-6000
X-ray powder diffractometer with Cu K.alpha. radiation. The
instrument was equipped with a long fine focus X-ray tube and a
curved graphite monochromator. The tube voltage and amperage were
set to 40 kV and 40 mA, respectively. The divergence and scattering
slits were set at 1.degree. and the receiving slit was set at 0.15
mm. Prior to the analysis, a silicon standard (NIST SRM 640c) was
analyzed to verify the Si 111 peak position. Diffraction radiation
was detected by a sodium iodide scintillation detector. Data were
collected and analyzed using XRD-6100/7000 software (v. 5.0).
Samples were prepared for analysis by placing them in a silicon
zero-background holder.
[0115] X-ray diffraction patterns presented herein are accompanied
by labeled peaks and/or tables with peak lists. Reported peak data,
under most circumstances, is within the range of up to about
30.degree. 2.theta.. Rounding algorithms were sometimes used to
round each peak to the nearest 0.1.degree. or 0.01.degree.
2.theta., depending upon the instrument used to collect the data
and/or the inherent peak resolution.
[0116] The location of reported peaks along the x-axis (degree
2.theta.) in the figures and the tables were automatically
determined using PATTERNMATCH.TM. 2.4.0 software and rounded to one
or two significant figures after the decimal point based upon the
above criteria. Peak position variability is given to within
.+-.0.1.degree. 2.theta. based upon recommendations outlined in the
USP discussion of variability in X-ray powder diffraction given in
United States Pharmacopeia, USP 31, NF 26, Vol. 1, p. 374. For
d-space listings, the wavelength used to calculate d-spacings was
1.541874 .ANG., a weighted average of the Cu-K.sub..alpha.1 and
Cu-K.sub..alpha.2 wavelengths [Phys. Rev., Vol. A56, No. 6, pp.
4554-4568 (1997)]. Variability associated with d-spacing estimates
was calculated from the USP recommendation at each d-spacing and is
provided in the respective data tables.
[0117] Differential Scanning Calorimetry (DSC)
[0118] DSC was performed using a TA Instruments Q2000 differential
scanning calorimeter. Temperature calibration was performed using
NIST traceable indium metal. The sample was placed into an aluminum
DSC pan, and the weight was accurately recorded. The pan was
covered with a lid perforated with a laser pinhole, and the lid was
crimped. A weighed, crimped aluminum pan was placed on the
reference side of the cell. The sample cell was equilibrated at
25.degree. C., in some cases cooled to -30.degree. C. and heated
under a nitrogen purge at a rate of 10.degree. C./minute, up to a
final temperature of 300.degree. C. Indium metal was used as the
calibration standard. Reported temperatures are at the transition
maxima. For studies on glass transition temperature (T.sub.g) of
amorphous material, the sample was equilibrated at -20.degree. C.,
and then heated under nitrogen at a rate of 1.degree. C./min., up
to 160.degree. C. The T.sub.g is reported from the inflection point
of the transition.
[0119] Differential Thermal Analysis (DTA)
[0120] DTA were performed simultaneously using a Seiko SSC 5200
TG/DTA instrument. Temperature calibration was performed using NIST
traceable indium metal. The sample was placed into an aluminum pan
and loosely covered with a lid and the weight accurately recorded.
The sample cell was equilibrated at 25.degree. C. and then heated
under a nitrogen purge at a rate of 10.degree. C./minute, up to a
final temperature of 300.degree. C. Reported temperatures are at
the transition maxima.
[0121] Thermogravimetric Analysis (TGA)
[0122] TGA was performed using a TA Instruments Q5000 IR
thermogravimetric analyzer or simultaneously with DTA/DSC a Seiko
SSC 5200 TG/DTA instrument. Temperature calibration was performed
using nickel and ALUMEL.TM.. Each sample was placed in an
aluminum/or/platinum pan. The pan was hermetically sealed with a
lid that was opened using a punching mechanism just before being
inserted into the TG furnace. The furnace was heated under nitrogen
at a rate of 10.degree. C./minute to a final temperature of
350.degree. C.
[0123] Thermogravimetric-Infrared (TG-IR) Analysis
[0124] TG-IR was preformed on a TA Instruments thermogravimetric
(TG) analyzer model 2050 interfaced to a Magna-IR 560.TM. Fourier
transform infrared (FT-IR) spectrophotometer (Thermo Nicolet)
equipped with an Ever-Glo mid/far IR source, a potassium bromide
(KBr) beam splitter and a mercury cadmium telluride (MCT-A)
detector. The FT-IR wavelength verification was performed using
polystyrene, and the TG calibration standards were nickel and
Alumel.TM.. The sample was placed in a platinum sample pan, and the
pan was inserted into the TG furnace. The TG instrument was started
first, immediately followed by the FT-IR instrument. The TG
instrument was operated under a flow of helium at 90 and 10 cc/min.
for the purge and balance, respectively. The furnace was heated
under nitrogen at a rate of 20.degree. C./minute to a final
temperature of 250.degree. C. IR spectra were collected
approximately every 32 seconds for approximately 13 minutes. Each
IR spectrum used 32 co-added scans collected at a spectral
resolution of 4 cm.sup.-1. Volatiles were identified from a search
of the High Resolution Nicolet Vapor Phase spectral library.
[0125] FT-Raman Spectroscopy
[0126] Raman spectra were acquired on a Nexus 670 FT-Raman
accessory module interfaced to a Nexus 670 FT-IR spectrophotometer
(Thermo Nicolet) equipped with an indium gallium arsenide (InGaAs)
detector. Wavelength verification was performed using sulfur and
cyclohexane. Each sample was prepared for analysis by placing the
sample into a glass tube and positioning the tube in a gold-coated
tube holder. Approximately 0.5 W of Nd:YVO.sub.4 laser power (1064
nm excitation wavelength) was used to irradiate the sample. Each
spectrum used 256 co-added scans collected at a spectral resolution
of 4 cm.sup.-1.
[0127] Raman spectra were also acquired on a Nexus 670 FT-Raman
accessory module interfaced to a Nexus 670 FT-IR spectrophotometer
(Thermo Nicolet) equipped with an indium gallium arsenide (InGaAs)
detector. Wavelength verification was performed using sulfur and
cyclohexane. Each sample was prepared for analysis by placing the
sample into a glass tube and positioning the tube in a gold-coated
tube holder.
[0128] Formulations
[0129] Formulations comprising Compound 1 as the active
pharmaceutical ingredient will have a significant percentage of
Compound 1 in one or more of its solid state forms, typically in
one or two solid state forms. Exemplary formulations contain at
least about 60% or usually at least about 90% of Compound 1 in one
solid state form. Formulations will usually comprise one or more
given solid state forms of Compound 1, substantially free of other
solid state forms, and one or more, typically 1, 2, 3 or 4
excipients or carriers. Other formulations can contain Compound 1
in one or more solid state forms, typically one or two. Other
formulations are generally solids, precipitates, gels, suspensions
and colloids that contain one or more solid state forms of Compound
1, such as the amorphous form of Compound 1, crystalline Form I or
crystalline Form III of Compound 1 or a mixture thereof. Preferred
formulations use a single crystalline form with Form I preferred.
Preferred oral unit dosages for human use will contain about 2 mg,
5 mg, 10 mg, 15 mg, 20 mg or 40 mg of a solid state form of
Compound 1 per unit dose, with 2 mg, 5 mg and 10 mg unit doses
preferred in treating chronic inflammation conditions in humans and
unit doses of 15 mg and 20 mg preferred for treating acute
inflammation conditions in humans.
[0130] While it is possible to administer Compound 1 in its solid
state as a pure compound to a subject, it is usually presented as a
solid formulation essentially free of liquid or less frequently a
solid suspension. Formulations will typically be used to prepare
unit dosages, e.g., tablets, capsules or lozenges for oral, buccal
or sublingual administration. Alternatively, embodiments include a
formulation for parenteral (e.g., subcutaneous, subdermal,
intravenous, intramuscular, intraperitoneal or aerosol)
administration made by the process of contacting a solid state form
of Compound 1, such as amorphous Compound 1, or a crystalline form
of Compound 1 (e.g., Form I), with a liquid excipient, e.g., any
one, two, three or more of water, buffered aqueous solution, PEG
100, PEG 200, PEG 300, PEG 400, propylene glycol, benzyl benzoate,
benzyl alcohol or ethanol, and optionally sterilizing the solution
and optionally dispensing the solution into vials or ampoules
(typically amber glass), which may be single-use or multi-use and
optionally storing the formulation at reduced temperature (about
0-12.degree. C., or about 2-10.degree. C.). Such formulations
optionally may also be used for oral administration and optionally
may contain one or more of a salt, buffer or bacteriostat or
preservative (e.g., NaCI, BHA, BHT or EDTA). Sometimes a surface
active agent is used to affect a suspension or is incorporated into
an oral solid dosage form to assist dissolution of the solid state
form of Compound 1, e.g., Form I, into the gastric tract. In
general, formulations for oral administration are preferred for
human therapeutic applications with solid oral formulations
particularly preferred.
[0131] Surface active agents used in a suspension or a solid form
of Compound 1 in a liquid excipient(s) include nonionic, cationic
and anionic surfactants. Examples of preferred surfactants include,
but are not limited to, a lauryl sulfate, sodium dodecyl sulfate,
polysorbate 40 and polysorbate 80.
[0132] In one embodiment, sodium lauryl sulfate is used as a
surface active agent in a unit dosage form, such as a tablet or a
capsule, for oral administration in treatment of a condition
disclosed herein wherein the formulation comprises crystalline Form
I essentially free of other solid state forms of Compound 1 and the
surface active agent, optionally comprising one or more additional
excipients.
[0133] Micronization
[0134] To improve dissolution rate of a crystalline form of
Compound 1 in a formulation comprising at least one crystalline
form of Compound 1 and one or more pharmaceutically acceptable
excipients in a solid dosage form or to affect suspendability in a
suspension for oral or parenteral administration comprising a
crystalline form of Compound 1 and a liquid excipient(s), the
crystalline form may be milled to an mean volume weighted particle
size (Dv, 50) or average diameter of about 0.01-200 .mu.m, or about
0.1-100 .mu.m or preferably about 3-50 .mu.m. Mean volume weighted
particle size (Dv, 50) or average diameter for milled crystalline
Compound 1 may thus be relatively small, e.g., about 0.1-1.0 .mu.m,
or somewhat larger, e.g., about 3-100 .mu.m. Milled crystalline
Compound 1 is suitable for preparing solid and suspension
formulations intended for oral or parenteral administration to a
subject. Preferably, mean volume weighted particle size (Dv, 50) or
average diameter are about 5, about 10, about 15 or about 20
micron. The particle size (Dv, 90) typically is about 5 micron,
about 10, about 15, about 20, about 25 or about 30 micron.
Preferred particle size has (Dv, 90) of .ltoreq.10 microns or (Dv,
90) of about 7 microns.
[0135] Micronization methods include milling by ball mills, pin
mills, jet mills (e.g., fluid energy jet mills) and grinding,
sieving and precipitation of a compound(s) from a solution, see,
e.g., U.S. Pat. Nos. 4,919,341; 5,202,129; 5,271,944; 5,424,077 and
5,455,049 (all of which are specifically incorporated herein by
reference). Particle size is determined by, e.g., transmission
electron microscopy, scanning electron microscopy, light
microscopy, X-ray diffractometry and light scattering methods or
Coulter counter analysis (see, for example, "Characterization of
Bulk Solids" D. McGlinchey, Ed., Blackwell Publishing, 2005).
[0136] Thus, crystalline Compound 1 may comprise or consist
essentially of a powder that contains one, two or more of these
mean volume weighted particle sizes or average diameter particle
sizes and the powder may be contacted with a solid excipient(s),
which can be mixed and optionally compressed or formed into a
desired shape. Alternatively, crystalline Compound 1 formed into a
powder a described above is contacted with a liquid excipient(s) to
prepare a liquid formulation or a liquid composition that is
incorporated into a solid formulation or suspension. Suitable
micronized formulations thus include aqueous or oily suspensions of
crystalline Compound 1.
[0137] Dosing Protocols or Methods
[0138] In treating any of the conditions or symptoms disclosed
herein, one can continuously (daily) or intermittently administer
the compositions or formulations comprising a crystalline or
amorphous form of Compound 1 to a subject suffering from or
susceptible to the condition or symptom, preferably administering a
formulation comprising Form I.
[0139] Dosages of Compound 1 in solid state form administered by
the routes described herein and the use of combination therapies
with other standard therapeutic agents or treatments could be
applied essentially as described above for any of the diseases or
conditions that are disclosed herein. Thus, the Compound 1 in solid
state form may be administered prophylactically or therapeutically
in chronic conditions or they may be administered at the time of or
relatively soon after an acute event such as a pain flare
associated with a condition being treated. Prophylactic
administration is used to reduce expected incidence or severity of
an event, e.g., a multiple sclerosis, arthritis or asthma
flare.
[0140] Preparation Methods of Solid State Forms
[0141] Crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
described in the Examples were obtained using one or more of the
following methods.
[0142] Fast Evaporation (FE): Saturated solutions of Compound 1
were prepared in various solvents as shown in Table 5 at ambient
temperature. The solutions were filtered into clean vials and
allowed to evaporate under ambient conditions, uncapped.
[0143] Very Fast Evaporation (VFE): A solution of Compound 1 was
prepared in ethanol at elevated temperature. The sample was
filtered into a clean petri dish and nitrogen was blown over the
sample to facilitate drying. The solids were collected and
immediately analyzed.
[0144] Slow Evaporation (SE): Saturated solutions of Compound 1
were prepared in various solvents as shown in Table 5 at ambient
temperature. The solutions were filtered into clean vials and these
vials were covered with aluminum foil. The foil was perforated with
small holes and allowed to evaporate under ambient conditions.
[0145] Slow Cool (SC): Saturated solutions of Compound 1 were
prepared in various solvents as shown in Table 5 at elevated
temperature. The solution was immediately filtered into a warm
vial. The vial was sealed and allowed to slowly cool. Solids that
formed were isolated by vacuum filtration and allowed to dry under
ambient conditions.
[0146] Ambient Temperature or Elevated Temperature Slurry: Samples
of Compound 1 were prepared in various solvents as shown in Table 5
so that excess solids were present in each vial. The mixtures were
agitated in a closed vial at either ambient temperature or at
elevated temperature using an orbital shaker. After several days
the solids were isolated by vacuum filtration and allowed to dry
under ambient conditions.
[0147] Crash Cooling (CC): Saturated solutions of Compound 1 were
prepared in various solvents as shown in Table 5 at either ambient
or elevated temperatures. The samples were thermally shocked by
quickly placing them at sub-ambient temperatures. After several
minutes, vials were checked for precipitation. In the absence of
precipitation, the vials were stored sub-ambient. Resulting solids
were isolated by vacuum filtration and typically air-dried at
ambient temperature.
[0148] Crash Precipitation (CP): Solutions of Compound 1 were
prepared in various solvents as shown in Table 5 at either elevated
or ambient temperature. The solutions were quickly filtered into
vials containing room temperature anti-solvent in order to induce
solid formation. After several minutes, vials were checked for
precipitation. In the absence of precipitation, the vials were
stored sub-ambient. Resulting solids were isolated by vacuum
filtration and typically air-dried at ambient temperature.
[0149] Liquid Vapor Diffusion (LVD): Saturated solutions of
Compound 1 were prepared in various solvents as shown in Table 5 at
ambient temperature. The solutions were filtered into clean vials
and placed uncapped in a larger vial that contained a diffusing
solvent. The larger vial was capped and left at ambient conditions
for several days. Resulting solids were isolated by vacuum
filtration and air-dried at ambient temperature.
[0150] Sonication: Super saturated solutions of Compound 1 were
prepared at ambient temperatures. The samples were briefly
subjected to probe sonication (Cole-Parmer Ultrasonic processor
with 3-mm probe). The samples were capped and left at ambient
temperature for nucleation/solid growth. Solids that were formed
after sonication were immediately isolated and dried under ambient
conditions.
NUMBERED EMBODIMENTS
[0151] Some preferred aspects of the invention and related subject
matter include the following numbered embodiments.
[0152] 1. A solid-state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
wherein the solid-state form is crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
amorphous form.
[0153] 2. The solid-state form of embodiment 1 wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
optionally substantially free of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol. In
this embodiment Form I Compound 1 is optionally characterized by an
X-ray powder diffraction pattern having three or four of degree
2-theta values selected from the group consisting of 10.4, 16.2,
17.8 and 28.8 and optionally with one or more degree 2-theta values
selected from the group consisting of 12.6, 15.1, 16.7 and 27.3.
One description of Form I Compound 1 has degree 2-theta values of
10.4, 16.2, 17.8 and 28.8 and optionally with a degree 2-theta
value of 15.0 or 27.3. Another description of Form I Compound 1 has
degree 2-theta values of 10.4, 16.2, 17.8 and 28.8 and optionally
with a degree 2-theta value of 16.1 and 27.3. Another exemplary
description of Form I Compound 1 has degree 2-theta values of 16.2,
17.8, 28.8 and 15.1.
[0154] 3. The solid-state form of embodiment 1 wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
characterized by a X-ray powder diffraction pattern substantially
identical to the X-ray powder diffraction pattern of FIG. 1, FIG. 2
or FIG. 3 and optionally a differential scanning calorimetry and
thermogravimetric analysis thermograms substantially identical to
the differential scanning calorimetry and thermogravimetric
analysis thermograms of FIG. 4.
[0155] 4. The solid-state form of embodiment 1, 2 or 3
characterized by or further characterized by a Raman spectrum
substantially identical to the Raman spectrum of FIG. 5. In this
embodiment Form I Compound 1 is characterized by one, two or three
Raman absorptions selected from the group consisting of 2993, 2974,
2947, 2937, 2887, 2860 and 2843 cm.sup.-1; optionally with one two
or three absorptions selected from the group consisting of 2106,
1674, 1467 and 1437 cm-1 or one, two or three absorptions selected
from the group consisting of 744, 712, 683, 484, 471, 457, 438, 247
and 226 cm.sup.-1. One description of Form I Compound 1 has Raman
absorptions at 2887, 2106, 1674, 1437 and 712 cm.sup.-1 and
optionally an absorption at 247 or 226 cm.sup.-1. Another
description of Form I Compound 1 has Raman absorptions at 2887,
2106, 1674, 1437, 712 and 683 cm.sup.-1 and optionally an
absorption at 484, 471 or 457. Another exemplary description of
Form I Compound 1 has Raman absorptions at 2106, 1674, 1437, 712
and 683 cm.sup.-1 and optionally with an absorption at 1467
cm.sup.-1.
[0156] 5. The solid-state form of embodiment 1 wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
optionally substantially free of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol. In
this embodiment Form II Compound 1 is optionally characterized by
an X-ray powder diffraction pattern having one, two or three degree
2-theta values selected from the group consisting of 2.5, 5.0 and
7.6 and two or more degree 2-theta values selected from the group
consisting of 10.4, 16.2, 17.8 and 28.8. One description of Form II
Compound 1 has degree 2-theta values of 2.5, 5.0 and 16.2 and
optionally with a degree 2-theta value of 10.4 or 28.8. Another
description of Form II Compound 1 has degree 2-theta values of 2.5,
16.2 and 28.8 and optionally with a degree 2-theta value of 10.4 or
17.8. Another exemplary description of Form II Compound 1 has
degree 2-theta values of 2.5, 5.0, 10.4, 16.2, 17.8 and 28.8.
[0157] 6. The solid-state form of embodiment 1 wherein the
crystalline material is Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
characterized by a X-ray powder diffraction pattern substantially
identical to the X-ray powder diffraction pattern of FIG. 6 and
optionally a differential scanning calorimetry and
thermogravimetric analysis thermograms substantially identical to
the differential scanning calorimetry and thermogravimetric
analysis thermograms of FIG. 7.
[0158] 7. The solid-state form of embodiment 1 wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
optionally free of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol. In
this embodiment Form III Compound 1 is optionally characterized by
an X-ray powder diffraction pattern having two or three degree
2-theta values selected from the group consisting of 15.2, 15.7,
16.6 and optionally with one or more degree 2-theta values selected
from the group consisting of 8.3, 12.3, 18.4 and 27.8. One
description of Form III Compound 1 has degree 2-theta values of
15.2, 16.6 and 27.8 and optionally with a degree 2-theta value of
8.3 or 12.3. Another description of Form III Compound 1 has degree
2-theta values of 15.2, 16.6 and 27.8 and optionally with a degree
2-theta value of 8.3 or 12.3. Another exemplary description of Form
III Compound 1 has degree 2-theta values of 15.2, 15.7, 16.6 and
27.8.
[0159] 8. The solid-state form of embodiment 1 wherein the
crystalline material is Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
characterized by a X-ray powder diffraction pattern substantially
identical to the X-ray powder diffraction pattern of FIG. 11 and
optionally a differential scanning calorimetry and
thermogravimetric analysis thermograms substantially identical to
the differential scanning calorimetry and thermogravimetric
analysis thermograms of FIG. 12.
[0160] 9. The solid-state form of embodiment 1, 8 or 9
characterized by or further characterized by a Raman spectrum
substantially identical to the Raman spectrum of FIG. 13. In this
embodiment Form III Compound 1 is characterized by one, two or
three Raman absorptions selected from the group consisting of 2985,
2966, 2950, 2933, 2893, 2853 and 2833 cm.sup.-1; optionally with
one two or three absorptions selected from the group consisting of
2108, 1666, 1469 and 1437 cm-1 or one, two or three absorptions
selected from the group consisting of 711, 681, 457, 436, 251 and
224 cm.sup.-1. One description of Form III Compound 1 has Raman
absorptions at 2950, 2934, 2108, 1666, 1437 and 711 cm.sup.-1 and
optionally an absorption at 250 or 224 cm.sup.-1. Another
description of Form III Compound 1 has Raman absorptions at 2985,
2950, 2108, 1437, 1666, 711 and 681 cm.sup.-1 and optionally an
absorption at 457 or 436 cm.sup.-1. Another exemplary description
of Form III Compound 1 has Raman absorptions at 2108, 1666, 1437,
712 and 681 cm.sup.-1 and optionally with an absorption at 1469
cm.sup.-1.
[0161] 10. The solid-state form of embodiment 1 wherein the
crystalline material is Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
optionally substantially free of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol. In
this embodiment Form IV Compound 1 is optionally characterized by
an X-ray powder diffraction pattern having two or three degree
2-theta values selected from the group consisting of 15.1, 15.7,
16.6 and optionally with one or more degree 2-theta values selected
from the group consisting of 8.3, 10.3, 12.3, 16.6 and 27.8. One
description of Form IV Compound 1 has degree 2-theta values of
15.1, 16.6 and 27.8 and optionally with a degree 2-theta value of
8.3 or 12.3. Another description of Form IV Compound 1 has degree
2-theta values of 15.7, 16.6 and 27.8 and optionally with a degree
2-theta value of 8.3, 12.3 or 16.6. Another exemplary description
of Form IV Compound 1 has degree 2-theta values of 8.3, 15.1, 15.7,
16.6 and 27.8.
[0162] 11. The solid-state form of embodiment 1 wherein the
crystalline material wherein the crystalline material is Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
characterized by a X-ray powder diffraction pattern substantially
identical to the X-ray powder diffraction pattern of FIG. 14 and
optionally a differential scanning calorimetry and
thermogravimetric analysis thermograms substantially identical to
the differential scanning calorimetry and thermogravimetric
analysis thermograms of FIG. 15.
[0163] 12. The solid-state form of embodiment 1, 10 or 11
characterized by or further characterized by a Raman spectrum
substantially identical to the Raman spectrum of FIG. 16. In this
embodiment Form IV Compound 1 is characterized by one, two or three
Raman absorptions selected from the group consisting of 2985, 2966,
2950, 2933, 2891, 2858 and 2833 cm.sup.-1; optionally with one, two
or three absorptions selected from the group consisting of 2108,
1666, 1469 and 1437 cm.sup.-1 or one, two or three absorptions
selected from the group consisting of 711, 681, 467, 457, 436 and
224 cm.sup.-1. One description of Form IV Compound 1 has Raman
absorptions at 2950, 2933, 2108, 1666, 1437 and 711 cm.sup.-1 and
optionally an absorbtion at 1469 or 457 cm.sup.-1. Another
description of Form IV Compound 1 has Raman absorptions at 2985,
2950, 2108, 1666, 1437, 711 and 681 cm.sup.-1 and optionally an
absorption at 467 or 457 cm.sup.-1. Another exemplary description
of Form IV Compound 1 has Raman absorptions at 2108, 1666, 1437,
711 and 681 cm.sup.-1 and optionally with an absorption at 1469
cm.sup.-1.
[0164] 13. A solid-state form of
17-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol wherein the
solid-state form is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form. 14. The solid state form of embodiment 13
essentially free of crystalline
17-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
optionally characterized by a X-ray powder diffraction pattern
substantially identical to the X-ray powder diffraction pattern of
FIG. 17 and optionally by a reversible heat flow in a modulated
differential scanning calorimetry thermogram substantially
identical to the reversible heat flow shown in FIG. 18.
[0165] 15. The solid state form of embodiment 13 or 14
characterized by or further characterized by a Raman spectrum
substantially identical to the Raman spectrum of FIG. 19. In this
embodiment amorphous Compound 1 is characterized by one, two or
three Raman absorptions selected from the group consisting of 2972,
2937, 2889 and 2858 cm.sup.-1; optionally with one two or three
absorptions selected from the group consisting of 2106, 1674 and
1439 cm.sup.-1 or one, two or three absorptions selected from the
group consisting of 748, 684, 484, 470, 436 and 226 cm.sup.-1. One
description of amorphous Compound 1 has Raman absorptions at 2972,
2106, 1674, 1439 and 684 cm.sup.-1 and optionally an absorption at
226 cm.sup.-1. Another description of amorphous Compound 1 has
Raman absorptions at 2937, 2106, 1674, 1439, 748 and 684 cm.sup.-1
and optionally an absorption at 484, 470 or 436. Another exemplary
description of amorphous Compound 1 has Raman absorptions at 2106,
1674, 1439 and 684 cm.sup.-1 and optionally with an absorption at
748 cm.sup.-1.
[0166] 16. A formulation comprising a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one pharmaceutically acceptable excipient.
[0167] 17. The formulation of embodiment 16 wherein said at least
one pharmaceutically acceptable excipient is sodium dodecyl
sulfate.
[0168] 18. The formulation of embodiment 16 wherein the
pharmaceutically acceptable excipients are sodium dodecyl sulfate,
microcrystalline cellulose and magnesium stearate.
[0169] 19. The formulation of embodiment 16, 17 or 18 wherein the
solid state form is
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form.
[0170] 20. The formulation of embodiment 19 wherein the crystalline
form is essentially free of amorphous of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0171] 21. The formulation of embodiment 20 wherein the crystalline
form is crystalline Form I essentially free of other crystalline
forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0172] 22. The formulation of embodiment 16, 17 or 18 wherein the
solid state form is
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
amorphous form.
[0173] 23. The formulation of embodiment 22 wherein the amorphous
form is essentially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form.
[0174] 24. A method to treat an inflammation condition comprising
administering to a human or mammal in need thereof an effective
amount of a formulation comprising a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one pharmaceutically acceptable excipient.
[0175] 25. The method of embodiment 24 wherein the inflammation
condition is an inflammatory bowel condition.
[0176] 26. The method of embodiment 24 wherein the inflammation
condition is an inflammatory lung condition.
[0177] 27. The method of embodiment 26 wherein the inflammatory
lung condition is cystic fibrosis, asthma, bronchitis or chronic
obstructive pulmonary disease.
[0178] 28. A method to treat metabolic syndrome, impaired glucose
tolerance (pre-diabetes) or a hyperglycemia condition comprising
administering to a human or mammal in need thereof an effective
amount of a formulation comprising a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one pharmaceutically acceptable excipient. In these
embodiments, patients having metabolic syndrome are usually
characterized as having three or more of the following five
conditions: hypertension, abdominal obesity (a waist circumference
of at least 102 cm in adult males and a waist circumference of at
least 88 cm in adult females), low HDL cholesterol (less than 40
mg/dL in adult males and less than 50 mg/dL in adult females),
elevated serum triglycerides (at least 150 mg/dL) and an elevated
fasting plasma glucose (at least 100 mg/dL). Patients having
impaired glucose tolerance are typically characterized as having a
fasting plasma glucose level of 100 mg/dL to 125 mg/dL and/or a
postprandial glucose level of 140-200, which is usually measured at
2 hours after ingestion of 75 g of anhydrous glucose in an oral
glucose tolerance test. Patients having impaired glucose tolerance
are typically considered pre-diabetic when postprandial glucose is
140-200 mg/dL. Impaired fasting glucose and impaired glucose
tolerance identifies individuals at risk for developing overt
diabetes mellitus over time. In preferred embodiments, the
treatment method is for treatment of impaired glucose tolerance. In
other preferred embodiments, the treatment method is for treatment
of hyperglycemia.
[0179] 29. The method of embodiment 28 wherein the hyperglycemia
condition is type 1 diabetes or type 2 diabetes. Patients having
diabetes that can be treated are typically characterized as having
a fasting plasma glucose level of at least 126 mg/dL and/or a
postprandial glucose level of at least 200 mg/dL. In preferred
embodiments, the hyperglycemia condition is type 2 diabetes.
[0180] 30. A method to treat inflammation associated with a
hyperproliferation condition comprising administering to a human or
mammal in need thereof an effective amount of a formulation
comprising a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one pharmaceutically acceptable excipient.
[0181] 31. The method of embodiment 30 wherein the
hyperproliferation condition is breast cancer, prostate cancer or
benign prostatic hyperplasia.
[0182] 32. A method to treat a neurodegenerative condition
comprising administering to a human or mammal in need thereof an
effective amount of a formulation comprising a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one pharmaceutically acceptable excipient. 33. The method
of embodiment 32 wherein the neurodegenerative condition is
Alzheimer's disease, Parkinson's disease or Amyotrophic Lateral
Sclerosis.
[0183] 34. A method to treat an autoimmune condition comprising
administering to a human or mammal in need thereof an effective
amount of a formulation comprising a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one pharmaceutically acceptable excipient.
[0184] 35. The method of embodiment 34 wherein the autoimmune
condition is multiple sclerosis, rheumatoid arthritis, ulcerative
colitis, Crohn's disease, Hashimotos' thyroiditis, Systemic Lupus
Erythematosus or optic neuritis.
[0185] 36. The method of any one of embodiments 24-35 wherein the
solid state form is Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol. In
these embodiments the Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol can
be essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, for
example, when used in (a) the method of embodiment 25, 29 or 30 or
(b) the method of embodiment 35 or 36.
[0186] 37. The method of any one of embodiments 24-35 wherein the
solid state form is Form I, Form II, Form III or Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or a
mixture thereof wherein the solid state form is essentially free of
amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol. In
these embodiments the Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol can
be essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, for
example, when used in (a) the method of embodiment 25, 29 or 30 or
(b) the method of embodiment 35 or 36.
[0187] 38. The method of any one of embodiments 24-35 wherein the
solid state form is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0188] 39. The method of any one of embodiments 24-35 wherein the
solid state form is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
wherein the solid state form is essentially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form.
[0189] Other embodiments of the invention related to
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
solid state form includes the following numbered embodiments.
[0190] 1A. A solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0191] 2A. The solid-state form of embodiment 1A wherein the
solid-state form is one or more crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0192] 3A. The solid-state form of embodiment 1A wherein
solid-state form is a polymorph or pseudopolymorph of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0193] 4A. The solid-state form of embodiment 1A wherein the
polymorph or pseudopolymorph of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0194] 5A. The solid-state form of embodiment 1A wherein the
solid-state form is a crystalline form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
is essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0195] 6A. The solid-state form of embodiment 1A wherein the
solid-state form is obtained from a slurry of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
methanol-water essentially as described in Example 1.
[0196] 7A. The solid-state form of embodiment 1A wherein the
solid-state form is obtained from a methanol-water solution
essentially as described in Example 2.
[0197] 8A. The solid-state form of embodiment 1A wherein the
solid-state form is prepared by micronization essentially as
described in Example 3.
[0198] 9A. The solid-state form of embodiment 1A wherein the
solid-state form is obtained from a tetrahydrofuran-methanol
solution essentially as described in Example 4.
[0199] 10A. The solid state form of embodiment 4A wherein the
solid-state form is characterized by: (a) an X-ray powder pattern
with degree 2-theta values of 10.41.+-.0.1, 16.20.+-.0.1 and
17.85.+-.0.1 and optionally one or more degree 2-theta values of
12.68.+-.0.1, 15.12.+-.0.1, 16.72.+-.0.1 and 20.91.+-.0.1 and
optionally with (b) differential scanning calorimetry (DSC)
thermogram having a prominent endotherm at about 266.degree. C.
(onset at about 259.degree. C.) obtained with a heating rate of
10.degree. C./min or (c) TGA thermogram with negligible weight loss
or .ltoreq.0.5% weight loss from about 30.degree. C. to about
200.degree. C., obtained with a heating rate of 10.degree. C./min
or is characterized by (a) and (b) or (a), (b) and (c).
[0200] 11A. The solid-state form of embodiment 4A wherein the
solid-state form is characterized by an X-ray powder diffraction
pattern and differential scanning calorimetry (DSC) thermogram
substantially identical to the X-ray powder diffraction pattern of
FIG. 1, FIG. 2 or FIG. 3 and optionally with DSC-TGA thermograms of
FIG. 4.
[0201] 12A. The solid-state form of embodiment 4A, 10A or 11A
characterized or further characterized by Raman spectrum
substantially identical to FIG. 5A or FIG. 5B or a Raman
spectroscopy spectrum with absorptions at peak positions of about
2106 and 1674 cm.sup.-1, optionally with one, two or three
absorptions with peak positions selected from the group consisting
of 2947, 2887, 976, 507, 484, 470, 370, 301, 247 and 226
cm.sup.-1.
[0202] 13A. The solid-state form of embodiment 4A, 10A or 11A
characterized or further characterized by crystals having the
morphology of FIG. 6A or FIG. 6B.
[0203] 14A. The solid state form of embodiment 4A wherein the
solid-state form is characterized by: (a) an X-ray powder pattern
with degree 2-theta values of 2.5, 5.0, 16.22.+-.0.1 and optionally
one or more 2-theta values of 7.6, 10.40, 12.66, 14.36, 15.08,
16.73, 17.75 and 18.29.+-.0.1 and optionally by (b) DSC thermogram
having a prominent endotherm at about 266.degree. C. (onset at
about 259.degree. C.) or (c) TGA thermogram with negligible weight
loss or .ltoreq.0.5% weight loss from about 30.degree. C. to about
200.degree. C., obtained with a heating rate of 10.degree. C./min
or is characterized by (a) and (b) or (a), (b) and (c).
[0204] 15A. The solid-state form of embodiment 4A wherein the
solid-state form is characterized by an X-ray powder diffraction
pattern and differential scanning calorimetry (DSC) thermogram
substantially identical to the X-ray powder diffraction pattern of
FIG. 7 and DSC-TGA thermograms of FIG. 8.
[0205] 16A. The solid state form of embodiment 4A wherein the
solid-state form is characterized by: (a) an X-ray powder pattern
with degree 2-theta values of 15.25, 15.64 and 16.60.+-.0.1 and
optionally one or more degree 2-theta values selected from the
group consisting of 8.35, 12.31, 18.25, 20.08 and 27.82.+-.0.1 and
optionally with (b) DSC thermogram having a prominent sharp
endotherm at about 266.degree. C. (onset at about 258.degree. C.)
and a prominent broad endotherm centered at about 105.degree. C.,
optionally with an endotherm at about 1.7.degree. C. or (c) TGA
thermogram with weight loss of about 9.6% from about 20.degree. C.
to about 100.degree. C., obtained with a heating rate of 10.degree.
C./min or is characterized by (a) and (b) or (a), (b) and (c).
[0206] 17A. The solid-state form of embodiment 4A wherein the
solid-state form is characterized by an X-ray powder diffraction
pattern and differential scanning calorimetry (DSC) thermogram
substantially identical to the X-ray powder diffraction pattern of
FIG. 11 and DSC-TGA thermograms of FIG. 12.
[0207] 18A. The solid-state form of embodiment 4A, 16A or 17A
characterized or further characterized by Raman spectrum
substantially identical to FIG. 13A or FIG. 13B or a Raman
spectroscopy spectrum with absorptions at peak positions of about
2108 and 1666 cm.sup.-1, optionally with one, two or three
absorptions with peak positions selected from the group consisting
of 2950, 2933, 1469, 983, 681, 654, 517, 380, 251 and 224
cm.sup.-1.
[0208] 19A. The solid state form of embodiment 4A wherein the
solid-state form is characterized by: (a) an X-ray powder pattern
with two or more 2-theta values selected from the group consisting
of 15.24, 15.66 and 16.62.+-.0.1 and optionally with one or more
2-theta values of 8.34, 10.50, 12.30, 16.23 and 27.78.+-.0.1 and
optionally with (b) DSC thermogram having a prominent sharp
endotherm at about 266.degree. C. (onset at about 257.degree. C.)
and a broad endotherm centered at about 98.degree. C., optionally
with a sharp endotherm at about 79.degree. C. or about 88.degree.
C. (c) TGA thermogram having about 9.0 or about 9.7 wt % weight
loss from about 20.degree. C. to about 110.degree. C. obtained with
a heating rate of 10.degree. C./min or is characterized by (a) and
(b) or (a), (b) and (c).
[0209] 20A. The solid-state form of embodiment 4A wherein the
solid-state form is characterized by an X-ray powder diffraction
pattern and differential scanning calorimetry (DSC) thermogram
substantially identical to the X-ray powder diffraction pattern of
FIG. 14 and DSC-TGA thermograms of FIG. 15.
[0210] 21A. The solid-state form of embodiment 4A, 19A or 20A
characterized or further characterized by Raman spectrum
substantially identical to FIG. 16A or a Raman spectroscopy
spectrum with absorptions at peak positions of about 2108 and 1666
cm.sup.-1, optionally with one, two or three absorptions with peak
positions selected from the group consisting of 2950, 2933, 1469,
983, 681, 654, 577, 467, 380, 251 and 224 cm.sup.-1.
[0211] 22A. The solid-state form of embodiment 1A wherein the
solid-state form is characterized by an X-ray powder diffraction
pattern and differential scanning calorimetry (DSC) thermogram
substantially identical to the X-ray powder diffraction pattern of
FIG. 17 and modulated DSC thermogram of FIG. 18.
[0212] 23A. The solid-state form of embodiment 1A or 23A
characterized or further characterized by Raman spectrum
substantially identical to FIG. 19A or FIG. 19B or a Raman spectrum
with absorptions at peak positions of about 2105 and 1673
cm.sup.-1; optionally with one, two or three peak positions
selected from the group consisting of 2972, 2937, 684, 538, 484,
470, 372 and 226 cm.sup.-1.
[0213] 24A. The solid-state form of embodiment 23A wherein the
solid-state form is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form.
[0214] 25A. The solid-state form of embodiment 1A wherein the
solid-state form is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form.
[0215] 26A. A formulation comprising or prepared from a solid state
form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one pharmaceutically acceptable excipient.
[0216] 27A. The formulation of embodiment 26A wherein the solid
state form is one or more crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0217] 28A. The formulation of embodiment 27A wherein said one
crystalline form is a polymorph or pseudopolymorph form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
is substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
amorphous form.
[0218] 29A. The formulation of embodiment 27A wherein said one
crystalline form is a polymorph or pseudopolymorph form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
is essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0219] 30A. The formulation of embodiment 27A wherein the
solid-state form is a single crystalline form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0220] 31A. The formulation of embodiment 30A wherein said one
single crystalline form is an anhydrate.
[0221] 32A. The formulation of embodiment 30A wherein the single
crystalline form is Form I.
[0222] 33A. The formulation of embodiment 28A or 29A wherein said
one crystalline form is a pseudopolymorph, optionally selected from
the group consisting of crystalline Form III and Form IV.
[0223] 34A. The formulation of embodiment 28A or 29A wherein said
one crystalline form is Form I substantially free or essentially
free of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0224] 35A. The formulation of embodiment 27A, 28A or 29A wherein
the crystalline form is, or is comprised of, crystalline Form
I.
[0225] 36A. The formulation of embodiment 27A, 28A or 29A wherein
the crystalline form is, or is comprised of crystalline Form
III.
[0226] 37A. The formulation of embodiment 27A, 28A or 29A wherein
the crystalline form is or is comprised of Form IV.
[0227] 38A. The formulation of embodiment 26A wherein the solid
state form is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0228] 39A. The formulation of embodiment 38A wherein amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0229] 40A. The formulation of any one of embodiments 26A-33A, 38A,
39A wherein the formulation is a solid formulation.
[0230] 41A. The formulation of any one of embodiments 26A-33A, 38A,
39A wherein the formulation is a liquid formulation prepared from a
solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0231] 42A. The formulation of embodiment 40A wherein the
formulation comprises
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
amorphous form.
[0232] 43A. The formulation of embodiment 40A wherein the
formulation comprises amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form.
[0233] 44A. The formulation of embodiment 41A wherein the
formulation is prepared from
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
amorphous form.
[0234] 45A. The formulation of embodiment 41A wherein the
formulation is prepared from amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
crystalline form.
[0235] 46A. The formulation of embodiment 40A wherein the solid
formulation is for oral dosing.
[0236] 47A. The formulation of embodiment 46A wherein said at least
one pharmaceutically acceptable excipient is a surface active agent
in an amount sufficient to provide 90% dissolution of the
formulation in water at ambient temperature after 30 min.
[0237] 48A. The formulation of embodiment 47A wherein the surface
active agent is sodium lauryl sulfate.
[0238] 49A. The formulation of 46A wherein the pharmaceutically
acceptable excipients are comprised of sodium lauryl sulfate,
microcrystalline cellulose and magnesium stearate.
[0239] 50A. The formulation of any one of embodiments 46A wherein
the pharmaceutically acceptable excipients consist essentially of
sodium lauryl sulfate, microcrystalline cellulose and magnesium
stearate in relative amounts to the solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol as
provided by Table 14 or Table 15.
[0240] 51A. An oral dosage form comprising a formulation of any one
of embodiments 26A-33A, 38A, 39A or a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0241] 52A. The oral dosage form of embodiment 51 wherein the
dosage form is a tablet or capsule.
[0242] 53A. A method to treat a hyperglycemic condition comprising
administering to a subject in need thereof an effective amount of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in a
solid state form or in a solid formulation comprising the solid
state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one pharmaceutically acceptable excipient.
[0243] 54A. The method of embodiment 53A wherein the solid state
form is a crystalline form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
amorphous form.
[0244] 55A. The method of embodiment 53A wherein the solid state
form is a polymorph or pseudopolymorph form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free or substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0245] 56A. The method of embodiment 55A wherein the polymorph form
is crystalline Form I.
[0246] 57A. The method of any one of embodiments 53A-56A wherein
the hyperglycemic condition is type 2 diabetes or metabolic
syndrome.
[0247] 58A. A method of preparing a solid formulation comprising
the step of blending a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol with
one, two, three or four other pharmaceutically acceptable
excipients.
[0248] 59A. The method of embodiment 58A wherein the solid state
form is crystalline Form I.
[0249] 60A. The method of embodiment 58A wherein the solid state
form is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0250] 61A. The method of embodiment 58A wherein one excipient is
sodium lauryl sulfate.
[0251] 62A. A method of preparing a liquid formulation comprising
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
a pharmaceutically acceptable excipients wherein at least one
excipient is a liquid excipient comprising the step of contacting
or admixing a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol with
the liquid excipient, optionally in the presence of another
excipient.
[0252] 63A. The method of embodiment 62A wherein the solid state
form is crystalline Form I.
[0253] 64A. The method of embodiment 62A wherein the solid state
form is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0254] 65A. A method to treat a hyperglycemic condition comprising
administering to a subject in need thereof an effective amount of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in a
liquid formulation prepared according to the method of embodiment
62A.
[0255] 66A. The method of embodiment 65A wherein the hyperglycemic
condition is Type 2 diabetes or metabolic syndrome.
[0256] 67A. A product, wherein the product is a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
prepared by the process according essentially to Example 1.
[0257] 68A. A product, wherein the product is a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
prepared by a process comprising the steps of (a) slurrying
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
75:25 by volume methanol:water; (b) drying solids obtained from
step (a) under vacuum (about 28 in Hg) at about 45.degree. C. to a
loss on drying of about 0.5%.
[0258] 69A. A product, wherein the product is a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
prepared by a process comprising the steps adding water sufficient
to maintain volume of a mixture of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
10:1 by weight methanol:water during distillation of the mixture at
ambient pressure to decrease by about 50% the initial volume
contributed by methanol wherein
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
present in between about 4-5% by weight relative to the total
initial volume.
[0259] 70A. The product of embodiment 69A wherein the process
further comprises the step of cooling the solution to a final
temperature between about 0-5.degree. C. and holding at the final
temperature for about 1 h.
[0260] 71A. A product prepared by a process comprising the step of
reducing in volume by 50% a solution of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
tetrahydrofuran:methanol in volume ratio of between about 5:1 to
10:1 wherein
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
present in weight to volume percent of between about 5-10% in
relation to the initial solution volume.
[0261] 72A. The product of embodiment 71A wherein the volume ratio
of tetrahydrofuran to water is about 6.5:1 and the weight to volume
percent of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol to
initial solvent volume is about 7.5%
[0262] Further aspects of the invention related to crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
includes the following numbered embodiments.
[0263] 1B. A crystalline form
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0264] 2B. The crystalline form of embodiment 1B wherein the
crystalline form is a pseudopolymorph, a polymorph or a mixture
thereof.
[0265] 3B. The crystalline form of embodiment 2B wherein the
pseudopolymorph is a solvate.
[0266] 4B. The crystalline form of embodiment 2B wherein the
crystalline form is a pseudopolymorph wherein the pseudopolymorph
consists essentially of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
an alcohol, water of hydration or a mixture thereof.
[0267] 5B. The crystalline form of embodiment 4B wherein the
alcohol is ethanol or methanol.
[0268] 6B. The crystalline form of embodiment 4B wherein the
pseudopolymorph is a single pseudopolymorph characterized by the
molecular formula of C.sub.21H.sub.30O.sub.3.1CH.sub.3OH,
C.sub.21H.sub.30O.sub.3.0.5 CH.sub.3OH.0.5 H.sub.2O,
C.sub.21H.sub.30O.sub.3.1H.sub.2O or
C.sub.21H.sub.30O.sub.3.2H.sub.2O.
[0269] 7B. The crystalline form of embodiment 3B wherein the
solvate is a hydrate.
[0270] 8B. The crystalline form of embodiment 7B wherein the
hydrate is the di-hydrate having the molecular formula of
C.sub.21H.sub.30O.sub.3.2H.sub.2O.
[0271] 9B. The crystalline form of embodiment 3B, 7B or 8B wherein
the pseudopolymorph is essentially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
other crystalline forms and has a thermal gravimetric analysis
thermogram with weight loss between about 9 to 10% from about
20.degree. C. to about 110.degree. C. obtained using a temperature
ramp of 10.degree. C./min.
[0272] 10B. The crystalline form of embodiment 3B, 7B or 8B wherein
the pseudopolymorph is a single polymorph essentially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
other crystalline forms and has a thermal gravimetric analysis
thermogram with weight loss of between about 9.0% to about 9.7%
from about 20.degree. C. to about 110.degree. C. obtained using a
temperature ramp of 10.degree. C./min.
[0273] 11B. The crystalline form of embodiment 3B wherein the
single pseudopolymorph is a solvate comprising methanol or
ethanol.
[0274] 12B. The crystalline form of embodiment 3B wherein the
pseudopolymorph is a solvate comprising water of hydration.
[0275] 13B. The crystalline form of embodiment 4B wherein the
pseudopolymorph is a single pseudopolymorph essentially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
other crystalline forms and has a thermal gravimetric analysis
thermogram essential identical to that provided in FIG. 12.
[0276] 14B. The crystalline form of embodiment 13B wherein the
single pseudopolymorph is crystalline Form III.
[0277] 15B. The crystalline form of embodiment 4B wherein the
pseudopolymorph is a single pseudopolymorph essentially free of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
other crystalline forms and has a thermal gravimetric analysis
thermogram essential identical to that provided in FIG. 15.
[0278] 16B. The crystalline form of embodiment 15B wherein the
single pseudopolymorph is crystalline Form IV.
[0279] 17B. The crystalline form of embodiment 1B wherein the
crystalline form is an anhydrate.
[0280] 18B. The crystalline form of embodiment 17B wherein the
anhydrate is a product prepared from a process comprising the step
of complete desolvation of crystalline Form III, Form IV or a
mixture thereof.
[0281] 19B. The crystalline form of embodiment 17B wherein the
anhydrate is, or is comprised of, crystalline Form I.
[0282] 20B. The crystalline form of embodiment 17B wherein the
anhydrate is, or is comprised of, crystalline Form II.
[0283] 21B. The crystalline form of embodiment 1B wherein the
crystalline form is characterized by one or more, typically 2, 3 or
4 XRPD prominent peaks in Table 1A, Table 1B or Table 4; optionally
with a prominent endotherm at about 266.degree. C. obtained by
differential scanning calorimetry using a temperature ramp of
10.degree. C./min or negligible weight loss when heated from about
20.degree. C. to about 100.degree. C. as determined by
thermogravimetric analysis (TGA) using a temperature ramp of
10.degree. C./min.
[0284] 22B. The crystalline form of embodiment 1B wherein the
crystalline form is characterized by one or more, typically 2, 3 or
4 XRPD prominent peaks in Table 1A, Table 1B or Table 4; optionally
with an apparent melting point of about 256.degree. C. as
determined in an open capillary tube.
[0285] 23B. The crystalline form of embodiment 1B wherein the
crystalline form is characterized by one or more, typically 2, 3 or
4 XRPD prominent peaks in Table 6; optionally with a prominent
endotherm at about 259.degree. C. obtained by differential scanning
calorimetry thermogram using a temperature ramp of 10.degree.
C./min.
[0286] 24B. The crystalline form of embodiment 1B wherein the
crystalline form is characterized by one or more, typically 2, 3 or
4 XRPD prominent peaks in Table 9; optionally with a prominent
endotherm at about 266.degree. C. or a broad endotherm centered at
about 105.degree. C. obtained by differential scanning calorimetry
thermogram using a temperature ramp of 10.degree. C./min or about
9.5% weight loss when heated from about 20.degree. C. to about
100.degree. C. as determined by thermogravimetric analysis (TGA)
using a temperature ramp of 10.degree. C./min.
[0287] 25B. The crystalline form of embodiment 1B wherein the
crystalline form is characterized by one or more, typically 2, 3 or
4 XRPD prominent peaks in Table 11; optionally with a prominent
endotherm at about 266.degree. C. obtained by differential scanning
calorimetry thermogram using a temperature ramp of 10.degree.
C./min or about 9.0% or about 9.7% loss when heated from about
30.degree. C. to 100.degree. C. as determined by thermogravimetric
analysis (TGA) using a temperature ramp of 10.degree. C./min.
[0288] 26B. The crystalline form of embodiment 1B wherein the
crystalline form is characterized by a pairwise distribution
function calculated from a XRPD pattern from FIG. 2.
[0289] 27B. The crystalline form of embodiment 1B wherein the
crystalline form is characterized by one or more prominent
absorptions, typically one, two or three prominent absorptions, in
the Raman spectrum of FIG. 5B.
[0290] 28B. The crystalline form of embodiment 1B wherein the
crystalline form is characterized by one or more prominent
absorptions, typically one, two or three absorptions, in the Raman
spectrum of FIG. 13B.
[0291] Further aspects of the invention related to crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
includes the following numbered embodiments.
[0292] 1C. Crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0293] 2C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 1C wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally as characterized an analytical method described herein
such as XRPD, DSC, TGA, TGA-IR analysis, melting point, Raman
spectroscopy, Karl Fisher and/or elemental analysis. Crystalline
forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
includes anhydrates, hydrates and solvates, which include mixed
water-solvent solvates. In these embodiments,
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol that
is substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol will
typically and preferably contain less than about 10% w/w or less
than about 7% w/w of the amorphous material.
[0294] 3C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 2C as Form III crystals. This form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is a
solvate material comprising water of hydration and is typically
substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0295] 4C. The crystalline Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 3C that contains less than about 10% w/w or less than
about 7% w/w of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally as characterized by an analytical method described
herein such as XRPD, DSC, TGA, TG-IR analysis, melting point or
Raman spectroscopy.
[0296] 5C. The crystalline Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 4C having (1) an XRPD pattern with prominent peaks of
15.64.+-.0.1 and 16.60.+-.0.1 degrees 28 and with optional
prominent peaks of 15.25.+-.0.1 and 27.82.+-.0.1 degrees 28;
optionally with (2) a DTA or DSC thermogram having a sharp
endotherm with onset at about 258.degree. C. and a broad endotherm
centered at about 105.degree. C. and (3) TGA thermogram with about
9.6% weight loss from about 19.degree. C. to about 100.degree. C.
using a temperature ramp of 10.degree. C./min.
[0297] 6C. The crystalline Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 4C or 5C having a Raman spectrum with one, two or three
prominent peaks of FIG. 13B or substantially identical to that
shown in FIG. 13B.
[0298] 7C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 2C as Form IV crystals. This form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is a
solvate comprising methanol and is typically substantially free of
amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0299] 8C. The crystalline Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 7C that contains less than about 10% w/w or less than
about 7% w/w of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally as characterized by an analytical method described
herein such as XRPD, DSC, TGA, TGA-IR, melting point or Raman
spectroscopy.
[0300] 9C. The crystalline Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 7C having (1) an XRPD pattern with prominent peaks at
15.66.+-.0.1 and 16.62.+-.0.1 degrees 28 and with optional
prominent peaks at 8.34.+-.0.1 and 15.24.+-.0.1 degrees 28;
optionally with (2) a DTA or DSC thermogram having an sharp
endotherm with onset between about 257.degree. C. to 258.degree. C.
and a broad endotherm centered at about 98.degree. C. and (3) TGA
thermogram with about 9.7% loss from about 17.degree. C. to about
110.degree. C. using a temperature ramp of 10.degree. C./min.
[0301] 10C. The crystalline Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 7C having (1) an XRPD pattern with prominent peaks at
15.66.+-.0.1 and 16.62.+-.0.1 degrees 28 and with optional
prominent peaks at 8.34.+-.0.1 and 15.24.+-.0.1 degrees 28;
optionally with (2) a DTA or DSC thermogram having an sharp
endotherm with onset between about 257.degree. C. to 258.degree. C.
and TGA thermogram with about 9% loss from about 30.degree. C. to
about 100.degree. C. using a temperature ramp of 10.degree.
C./min.
[0302] 11C. The crystalline Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 8C, 9C or 10C having a Raman trace with one, two or
three prominent peaks of FIG. 19B or substantially identical to
that shown in FIG. 19B.
[0303] 12C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 2C wherein the crystalline form is characterized by
sufficient bioavailability of the crystalline material to be
suitable for once daily or twice daily administration of unit oral
doses of 5 mg, 10 mg, 15 mg, 20 mg or 50 mg to a human, such as a
human having a hyperglycemic or autoimmune condition.
[0304] 13C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 12C wherein the crystalline form is characterized by
sufficient stability on storage at 65.degree. C. and 75% relative
humidity for at least 6 months wherein sufficient stability is
characterized by a change of less than about 5% w/w in the
degradation of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol to a
degradant or by conversion of less than about 5% w/w to another
solid state form.
[0305] 14C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 13C wherein the crystalline form is or is comprised of
Form I.
[0306] 15C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 2C as Form I crystals. This form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
an anhydrate and does not contain a solvent as measured by an
analytical method described herein such as Karl Fisher titration
and/or elemental analysis and/or TG-IR analysis and in preferred
embodiments it is substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally as measured by an analytical method described herein
such as XRPD, DSC/DTA, TGA, Raman spectroscopy or solid state NMR
spectroscopy
[0307] 16C. The crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 14C that contains less than about 10% w/w or less than
about 7% w/w of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally as characterized by an analytical method described
herein such as XRPD, DSC/DTA, TGA, Raman spectroscopy or solid
state NMR spectroscopy.
[0308] 17C. The crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 16C having an XRPD pattern with prominent peaks at
16.2.+-.0.1, 16.7.+-.0.1 and 17.8.+-.0.1 degrees 2-theta and
optional prominent peaks at 10.4.+-.0.1, 12.6.+-.0.1, 15.1.+-.0.1
degrees 2-theta; optionally with (2) a DTA or DSC thermogram having
an endotherm with onset at about 258.degree. C. and TGA thermogram
with negligible wt % loss in a temperature range of about
30.degree. C. to about 100.degree. C. using a temperature ramp of
10.degree. C./min.
[0309] 18C. The crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 17C wherein the crystals have the morphology of tablets
or needles.
[0310] 19C. The crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 16C or 17C having a Raman trace with one, two or three
prominent peaks of FIG. 5 or substantially identical to that shown
in FIG. 5B.
[0311] 20C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 12C wherein the crystalline form is, or is comprised of,
Form II.
[0312] 21C. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 2C as Form II crystals. This form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
an anhydrate as determined by an analytical method described herein
such as Karl Fisher titration and/or elemental analysis and/or TGA
and in preferred embodiments it is substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally as measured by an analytical method described herein
such as XRPD, DSC/DTA, TGA, Raman spectroscopy or solid state NMR
spectroscopy
[0313] 22C. The crystalline Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 21C that contains less than about 10% w/w or less than
about 7% w/w of other crystalline forms of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally as characterized by an analytical method described
herein such as XRPD, DSC/DTA, TGA, Raman spectroscopy or solid
state NMR spectroscopy.
[0314] 23C. The crystalline Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 21C having an XRPD pattern with prominent peaks at
2.5.+-.0.1, 5.0.+-.0.1 and 16.2.+-.0.1 degree 2-theta; optionally
with prominent peaks at 7.6.+-.0.1, 10.4.+-.0.1, 17.8.+-.0.1 degree
2-theta and (2) a DTA or DSC thermogram having an sharp endotherm
at 266.degree. C. and TGA thermogram with negligible wt % loss in a
temperature range of about 30.degree. C. to about 100.degree. C.
using a temperature ramp of 10.degree. C./min.
[0315] 24C. Use of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, or
use of a composition comprising one or more excipients and
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, for
the preparation of a medicament for the treatment or prophylaxis of
a hyperglycemic or autoimmune condition. In these embodiments, the
use of crystalline Forms I or Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
preferred, with Form I most preferred. In these uses appreciable
amounts of two crystal forms can be present, but there is
preferably only 1 crystalline form present, e.g., a single crystal
form comprises at least about 90% w/w or at least about 93% w/w of
the 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
that is present.
[0316] 25C. The use according to embodiment 24C wherein the
autoimmune condition is type 1 diabetes, rheumatoid arthritis,
ulcerative colitis or Hashimotos'thyroiditis and the hyperglycemic
condition is type 2 diabetes or metabolic syndrome
[0317] 26C. The use according to embodiment 25C wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally as characterized by an analytical method described
herein such as XRPD, DSC/DTA, TGA, TGA-IR, Raman spectroscopy
and/or solid state NMR.
[0318] 27C. A method to make crystalline
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of (i) reducing in volume a solution of
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol in
methanol-water, methanol-tetrahydrofuran or acetone, optionally
under vacuum and/or with heating at about 35.degree. C. to about
70.degree. C., or (ii) removing methanol from a solution of
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol in
methanol-water by distillation concomitant with addition of water
wherein the initial volume of the solution is substantially
maintained, or (iii) removing ethanol from a solution of
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol in
ethanol by evaporation, optionally under vacuum and/or with heating
at about 35.degree. C. to about 80.degree. C., or (iv) slurrying or
mixing
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol in
isopropanol or in methyl ethyl ketone, or (v) precipitating with
water a solution of
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol in
ethanol, optionally at a temperature of about 0.degree. C. to about
35.degree. C., or (vi) reducing the volume of a solution of
17.alpha.-ethynylandrost-5-ene-3.beta.,7.beta.,17.beta.-triol in
methanol-chloroform, optionally under vacuum and/or with heating at
about 35.degree. C. to about 65.degree. C.
[0319] Further aspects of the invention related to amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
include the following numbered embodiments.
[0320] 1D. Amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0321] 2D. The amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 1D wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol as
measured by XRPD analysis, optionally wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline Form I and/or Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0322] 3D. The amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 1D wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol as
measured by XRPD analysis, optionally wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline Form I.
[0323] 4D. The amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 1D wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol as
measured by XRPD analysis, optionally wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline Form I and Form II.
[0324] 4D. The amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 1D wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
contains less than about 8% w/w of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0325] 5D. The amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 1D wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
contains less than about 5% w/w of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0326] 5D. A pharmaceutical formulation comprising one or more
excipients and amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
as described in any one of embodiments 1D-4D.
[0327] 6D. A product, wherein the product is amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
produced by a process comprising the step of lyophilization of a
mixture of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
t-butanol.
[0328] 7D. The product of embodiment 6D wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol I
(1) is substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol as
measured by XRPD analysis, or (2) contains less than about 8% w/w
of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, or
(3) contains less than about 5% w/w of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
optionally wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0329] 8D. Use of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, or
use of a composition comprising one or more excipients and
amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol for
the preparation of a medicament for the treatment or prophylaxis of
a hyperglycemic or autoimmune condition.
[0330] 9D. The use according to embodiment 8D wherein the
autoimmune condition is type 1 diabetes, rheumatoid arthritis,
ulcerative colitis or Hashimotos' thyroiditis and the hyperglycemic
condition is type 2 diabetes or metabolic syndrome. In these uses,
amorphous material preferably comprises at least about 90% w/w or
at least about 95% w/w of the
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol that
is present.
[0331] 10D. The use according to embodiment 9D wherein the
amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol as
measured by XRPD analysis or wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
contains less than about 8% w/w or less than about 5% w/w of
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0332] 1E. Crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0333] 2E. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 1E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0334] 3E. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 2E wherein the crystalline form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
an anhydrate or is characterized by a negligible weight loss or a
weight loss of about 0.5% or less when heated between about
40.degree. C. to about 105.degree. C. using a temperature ramp of
10.degree. C./min.
[0335] 4E. The crystalline anhydrate of embodiment 3E wherein the
anhydrate is Form I or Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or a
mixture thereof.
[0336] 5E. The crystalline anhydrate of embodiment 4E wherein the
anhydrate is Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0337] 6E. The crystalline anhydrate of embodiment 5E wherein Form
I 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by or has an X-ray powder diffraction pattern with
peak positions of 10.38.+-.0.1, 16.20.+-.0.1 and 17.75.+-.0.1
degrees 2-theta, optionally with one, two or three peak positions
selected from the group consisting of 12.66.+-.0.1, 15.10.+-.0.1,
16.73.+-.0.1, 28.92.+-.0.1 degrees 2-theta.
[0338] 7E. The crystalline anhydrate of embodiment 6E wherein the
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
further characterized by or has a differential scanning calorimetry
thermogram with a prominent endotherm at about 266.degree. C.
obtained using a temperature ramp of 10.degree. C./min.
[0339] 8E. The crystalline anhydrate of embodiment 5E wherein Form
I 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of Form II, Form III and Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or
wherein Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprises at least about 90% w/w of all crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol that
is present.
[0340] 9E. The crystalline anhydrate of any one of embodiments
5E-8E wherein Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol has
a Raman spectroscopy spectrum with peak positions at about 2105 and
1673 cm.sup.-1, optionally with one, two or three peak positions
selected from the group consisting of about 2887, 1467, 1437, 833,
712, 681, 484, 470, 457, 247 and 226 cm.sup.-1 or substantially
identical to that of FIG. 5A or FIG. 5B.
[0341] 10E. The crystalline anhydrate of embodiment 6E wherein the
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by or has a single crystal X-ray crystallography
space group of P2.sub.12.sub.12.sub.1 (#19).
[0342] 11E. The crystalline anhydrate of embodiment 8E wherein the
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by morphology of FIG. 6A or FIG. 6B.
[0343] 12E. The crystalline anhydrate of embodiment 8E wherein the
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by morphology of blades or plates.
[0344] 13E. The crystalline anhydrate of embodiment 4E wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is a
mixture of Form II and Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of Form III and Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0345] 14E. The crystalline anhydrate of embodiment 4E wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0346] 15E. The crystalline anhydrate of embodiment 14E wherein
Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by or has an X-ray powder diffraction pattern with
peak positions of 2.49.+-.0.1, 5.04.+-.0.1 and 16.20.+-.0.1 degrees
2-theta, optionally with one two or three peak positions selected
from the group consisting of 10.44.+-.0.1, 12.69.+-.0.1,
15.12.+-.0.1, 16.71.+-.0.1, 17.73.+-.0.1 and 28.92.+-.0.1 degrees
2-theta.
[0347] 16E. The crystalline anhydrate of embodiment 14E wherein
Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
further characterized by or has a differential scanning calorimetry
thermogram with a prominent endotherm at about 259.degree. C.,
optionally with a week exotherm centered at about 207.degree. C.,
obtained using a temperature ramp of 10.degree. C./min.
[0348] 17E. The crystalline anhydrate of embodiment 13E wherein
Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of Form I, Form III and Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or
wherein Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprises at least about 90% w/w of all crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol that
is present.
[0349] 18E. The crystalline anhydrate of embodiment 14E wherein the
Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by or has a single crystal X-ray crystallography
space group of P2.sub.12.sub.12 (#18).
[0350] 19E. The crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 2E wherein the crystalline form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is a
solvate or is characterized by a weight loss of BLANK when heated
between about 40.degree. C. to about 105.degree. C. using a
temperature ramp of 10.degree. C./min.
[0351] 20E. The crystalline solvate of embodiment 19E wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form III or Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or a
mixture thereof.
[0352] 21E. The crystalline solvate of embodiment 20E wherein the
solvate is Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of Form I and Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0353] 22E. The crystalline solvate of embodiment 21E wherein Form
III 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
is characterized by or has an X-ray powder diffraction pattern with
peak positions of 15.24.+-.0.1, 15.66.+-.0.1 and 16.62.+-.0.1,
degrees 2-theta, optionally with one two or three peak positions
selected from the group consisting of 8.37.+-.0.1, 12.30.+-.0.1 and
27.78.+-.0.1 degrees 2-theta.
[0354] 23E. The crystalline solvate of embodiment 20E wherein Form
III 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
is further characterized by or has a differential scanning
calorimetry thermogram with a prominent endotherm at about
266.degree. C. or a broad endotherm centered at about 105.degree.
C. or 107.degree. C. and optionally with a endotherm at about
1.7.degree. C. or about 2.3.degree. C. obtained using a temperature
ramp of 10.degree. C./min.
[0355] 24E. The crystalline solvate of embodiment 19E wherein Form
III 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
is substantially free of Form I, Form II or Form IV and Form V
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or
wherein Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprises at least about 90% w/w of all crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol that
is present.
[0356] 25E. The crystalline anhydrate of any one of embodiments
21E-24E wherein Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by or has a Raman spectroscopy spectrum with peak
positions at about 2108 and 1666 cm.sup.-1, optionally with one,
two or three peak positions selected from the group consisting of
about 2950, 1469, 1437, 711, 681, 251 and 224 cm.sup.-1 or
substantially identical to that of FIG. 13A or FIG. 13B.
[0357] 26E. The crystalline solvate of embodiment 19E wherein the
solvate is Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
substantially free of Form I and Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0358] 27E. The crystalline solvate of embodiment 26E wherein Form
IV 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
is characterized by or has an X-ray powder diffraction pattern with
peak positions of 15.24.+-.0.1, 15.66.+-.0.1 and 16.62.+-.0.1
degrees 2-theta, optionally with one two or three peak positions
selected from the group consisting of 8.34.+-.0.1, 10.50.+-.0.1,
12.30.+-.0.1, 16.23.+-.0.1 and 27.78.+-.0.1 degrees 2-theta.
[0359] 28E. The crystalline solvate of embodiment 27E wherein Form
IV 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
is further characterized by or has a differential scanning
calorimetry thermogram with a prominent endotherm at about
266.degree. C. or a broad endotherm centered at about 98.degree. C.
and optionally with a sharp endotherm between about 75-90.degree.
C. obtained using a temperature ramp of 10.degree. C./min.
[0360] 29E. The crystalline solvate of embodiment 19E wherein Form
IV 17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
is substantially free of Form I, Form II and Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or
wherein Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprises at least about 90% w/w of all crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol that
is present.
[0361] 30E. The crystalline solvate of any one of embodiments
19E-24E wherein Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by or has a Raman spectroscopy spectrum with peak
positions at about 2107 and 1666 cm-1, optionally with one, two or
three peak positions selected from the group consisting of about
2950, 1469, 1437, 711, 467, 457 and 224 cm.sup.-1 or substantially
identical to that of FIG. 13A or FIG. 13B.
[0362] 31E. The crystalline solvate of embodiment 19E wherein the
solvate comprises at least one C.sub.1-6 alcohol, water or a
combination thereof.
[0363] 32E. The crystalline solvate of embodiment 31E wherein the
solvate consists essentially of a C.sub.1-6 alcohol or a C.sub.1-6
alcohol and water of hydration.
[0364] 33E. The crystalline solvate of embodiment 32E wherein the
C.sub.1-6 alcohol is ethanol or methanol.
[0365] 34E. The crystalline solvate of embodiment 19E wherein the
solvate consists essentially of water of hydration.
[0366] 35E. The crystalline solvate of embodiment 28E wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form IV or Form V
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0367] 36E. The crystalline solvate of embodiment 31E wherein the
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form III or Form IV, wherein the Form III or Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline Form I and Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0368] 37E. Amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0369] 38E. The amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 37E wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or
contains less than about 10% w/w of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0370] 39E. The amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol of
embodiment 40E wherein the wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by or has (1) an X-ray powder diffraction pattern
with a broad band at about 16 degree 2 theta or X-ray powder
diffraction pattern substantially as shown at FIG. 17; (2) a
thermogravimetric analysis thermogram weight loss of between about
11-12% when heated from about 30.degree. C. to about 110.degree. C.
or a weight loss of between about 15-17% when heated from about
30.degree. C. to about 200.degree. C., obtained using a temperature
ramp of 10.degree. C./min;
[0371] (3) a modulated DSC thermal analysis thermogram that provide
a glass transition temperature of about 44.degree. C. obtained
using a temperature ramp of 1.degree. C./min or (4) a combination
of the characteristics described at (1) and (2) or (1) and (3).
[0372] 40E. A method to make crystalline anhydrate Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of recovering
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol from
a mixture of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
methanol and water.
[0373] 41E. A method to make crystalline anhydrate Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of recovering
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol from
a mixture of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
methyl ethyl ketone or ethyl acetate.
[0374] 42E. A method to make crystalline anhydrate Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of recovering
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol from
a mixture of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
methanol and chloroform.
[0375] 43E. A method to make crystalline anhydrate Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of recovering
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol from
a mixture of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
ethanol and water.
[0376] 44E. A formulation comprising one or more excipients and
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0377] 45E. The formulation of embodiment 44E wherein the
formulation is a solid formulation, optionally tablets, capsules or
another unit dosage form suitable for oral administration.
[0378] 46E. A method of preparing a formulation comprising the step
of contacting, mixing and/or blending amorphous or crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol or a
mixture thereof with one, two, three, four or more excipients to
obtain a mixture and processing the mixture to obtain a
formulation, optionally wherein the formulation is a solid
formulation or comprises unit dosages suitable for oral
administration to humans, optionally tablets, caplets or
capsules.
[0379] 47E. The method of embodiment 46E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is a
solvate.
[0380] 48E. The method of embodiment 47E wherein the crystalline
solvate comprises ethanol or methanol and water of hydration.
[0381] 49E. The method of embodiment 47E wherein the crystalline
solvate consists essentially of water of hydration.
[0382] 50E. The method of embodiment 47E wherein the solvate is
Form III or Form IV or a mixture thereof.
[0383] 51E. The method of embodiment 46E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
an anhydrate.
[0384] 52E. The method of embodiment 51E wherein the crystalline
anhydrate is Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0385] 53E. The method of embodiment 46E wherein at least one
excipient is a surface active agent, optionally sodium lauryl
sulfate or Polysorbate-80
[0386] 54E. The method of embodiment 46E wherein at least one
excipient is a liquid vehicle, optionally wherein the formulation
is a liquid formulation.
[0387] 55E. The method of embodiment 54E wherein another excipient
is a cyclodextrin.
[0388] 56E. The method of embodiment 55E wherein the cyclodextrin
is sulfobutylether-13-cyclodextrin or
hydroxypropyl-13-cyclodextrin.
[0389] 57E. A method to treat a inflammation condition in a subject
comprising administering to the subject or delivering to the
subject's tissues an effective amount of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, a
formulation comprising crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one or more excipients or a formulation prepared from
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
one, two, three, four or more excipients.
[0390] 58E. The method of embodiment 57E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form I or Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
essentially free of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0391] 59E. The method of embodiment 57E wherein the inflammation
condition is a metabolic condition.
[0392] 60E. The method of embodiment 59E wherein the metabolic
condition is a hyperglycemic condition.
[0393] 61E. The method of 60E wherein the metabolic condition is
type 1 diabetes, type 2 diabetes or metabolic syndrome.
[0394] 62E. The method of embodiment 57E wherein the inflammation
condition is an autoimmune condition.
[0395] 63E. The method of embodiment 62E wherein the autoimmune
condition is multiple sclerosis, rheumatoid arthritis or ulcerative
colitis.
[0396] 64E. The method of embodiment 57E wherein the inflammation
condition is a hyperproliferation condition.
[0397] 65E. The method of embodiment 64E wherein the
hyperproliferation condition is prostate cancer, breast cancer or
benign prostatic hyperplasia.
[0398] 66E. The method of embodiment 57E wherein the inflammation
condition is a bowel inflammation condition.
[0399] 67E. The method of embodiment 66E wherein the bowel
inflammation condition is ulcerative colitis, Crohn's disease or
inflammatory bowel syndrome.
[0400] 68E. The method of embodiment 57E wherein the inflammation
condition is a lung inflammation condition.
[0401] 69E. The method of embodiment 68E wherein the lung
inflammation condition is asthma, COPD or cystic fibrosis.
[0402] 70E. The method of embodiment 57E wherein the inflammation
condition is a neurodegenerative condition.
[0403] 71E. The method of embodiment 70E wherein the
neurodegenerative condition is Parkinson's disease, Alzheimer's
disease or Amyotrophic Lateral Sclerosis.
[0404] 72E. A method to treat a inflammation condition in a subject
comprising administering to the subject or delivering to the
subject's tissues an effective amount of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, a
formulation comprising amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one or more excipients or a formulation prepared from
amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
one, two, three, four or more excipients.
[0405] 73E. The method of embodiment 72E wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
substantially free of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0406] 74E. The method of embodiment 72E wherein the inflammation
condition is a metabolic condition.
[0407] 75E. The method of embodiment 74E wherein the metabolic
condition is a hyperglycemic condition.
[0408] 76E. The method of embodiment 75E wherein the metabolic
condition is type 1 diabetes, type 2 diabetes or metabolic
syndrome.
[0409] 77E. The method of embodiment 72E wherein the inflammation
condition is an autoimmune condition.
[0410] 78E. The method of embodiment 77E wherein the autoimmune
condition is Type 1 diabetes, multiple sclerosis, rheumatoid
arthritis or ulcerative colitis.
[0411] 79E. The method of embodiment 72E wherein the inflammation
condition is a hyperproliferation condition.
[0412] 80E. The method of embodiment 79E wherein the
hyperproliferation condition is prostate cancer, breast cancer or
benign prostatic hyperplasia.
[0413] 81E. The method of embodiment 72E wherein the inflammation
condition is a bowel inflammation condition.
[0414] 82E. The method of embodiment 81E wherein the bowel
inflammation condition is ulcerative colitis, Crohn's disease or
inflammatory bowel syndrome.
[0415] 83E. The method of embodiment 72E wherein the inflammation
condition is a lung inflammation condition.
[0416] 84E. The method of embodiment 83E wherein the lung
inflammation condition is asthma, COPD or cystic fibrosis.
[0417] 85E. The method of embodiment 72E wherein the inflammation
condition is a neurodegenerative condition.
[0418] 86E. The method of embodiment 85E wherein the
neurodegenerative condition is Parkinson's disease, Alzheimer's
disease or Amyotrophic Lateral Sclerosis.
[0419] 87E. Use of crystalline or amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, or
use of a composition comprising one or more pharmaceutically
acceptable excipients and crystalline or amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, for
the preparation of a medicament.
[0420] 88E. Use of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, or
use of a composition comprising one or more excipients and
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, for
the preparation of a medicament for the treatment or prophylaxis of
an inflammation condition.
[0421] 89E. A crystalline anhydrate of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
wherein the crystalline anhydrate is characterized by or has an
X-ray crystallography space group of P2.sub.12.sub.12.sub.1
(#19).
[0422] 90E. A crystalline anhydrate of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol that
is characterized by or has unit cell parameters in angstroms of
a=11.740, b=12.273, c=12.339, .alpha.=90.degree.,
.beta.=90.degree., .gamma.=90.degree., Z'/Z=1/4 and unit cell
volume of 1777.9 .ANG..sup.3 determined from indexing the XRPD
pattern in FIG. 1B.
[0423] 91E. A crystalline anhydrate of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
wherein the crystalline anhydrate is characterized by or has an
X-ray crystallography space group of P2.sub.12.sub.12 (#18).
[0424] 92E. A crystalline anhydrate of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
wherein the crystalline anhydrate is characterized by or has unit
cell parameters a=12.273, b=12.339, c=35.220, .alpha.=90.degree.,
.beta.=90.degree., .gamma.=90.degree., Z'/Z=3/12 and unit cell
volume of 5333.6 .ANG..sup.3 determined from indexing the XRPD
pattern of FIG. 1B and symmetry reduction of the unit cell
determined therefrom.
[0425] 93E. A crystalline solvate
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
wherein the crystalline solvate comprises at least one C.sub.1-4
alcohol, water or a combination thereof.
[0426] 94E. The crystalline solvate of embodiment 93E wherein the
solvate is a hydrate.
[0427] 95E. Amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
wherein the amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
characterized by an amorphous X-ray halo or an XRPD pattern
substantially identical to the XRPD pattern of FIG. 18 optionally
characterized by Raman absorptions at 2105 and 1673 cm.sup.-1 and
optionally with one, two or three absorptions selected from the
group consisting of 2971, 2938, 2890 and 2859 cm.sup.-1.
[0428] 96E. A method to make crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of reducing in volume a solution of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
methanol-water, methanol-tetrahydrofuran or acetone or removing
methanol from a solution of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
methanol-water by distillation concommitant with addition of water
wherein the initial volume of the solution is substantially
maintained or removing solvent from a solution of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
ethanol by evaporation or slurrying
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
isopropanol.
[0429] 97E. The method of embodiment 95E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
crystalline Form I needles.
[0430] 98E. The method of embodiment 96E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
crystalline Form I tablets.
[0431] 99E. The method of embodiment 96E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
crystalline Form I plates or blades.
[0432] 100E. A method to make Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of slurrying
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
methyl ethyl ketone.
[0433] 101E. A method to make Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of precipitating with water a solution of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
ethanol.
[0434] 102E. A method to make Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of reducing in volume a solution of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
methanol-chloroform.
[0435] 103E. A method to make amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
comprising the step of removing solvent from a solution of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
t-butanol by lyophilization.
[0436] 104E. A formulation comprising one or more excipients and
crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0437] 105E. The formulation of embodiment 104E wherein the
formulation is a solid formulation, optionally tablets, capsules or
another unit dosage form suitable for oral administration.
[0438] 106E. A method of preparing a formulation comprising the
step of contacting, mixing and/or blending amorphous or crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol with
one, two, three, four or more excipients to obtain a mixture and
processing the mixture to obtain a formulation, wherein the
formulation is a solid formulation, a liquid formulation or
comprises unit dosages suitable for oral administration to humans
wherein the unit dosages are tablets, caplets or capsules.
[0439] 107E. The method of embodiment 106E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is a
solvate.
[0440] 108E. The method of embodiment 107E wherein the crystalline
solvate is a hydrate.
[0441] 109E. The method of embodiment 106E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
an anhydrate.
[0442] 110E. The method of embodiment 109E wherein the crystalline
anhydrate is Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0443] 111E. The method of embodiment 106E wherein at least one of
the excipients is a surface active agent.
[0444] 112E. The method of embodiment 111E wherein said at least
one excipient is a lauryl sulfate salt or Polysorbate-80 and
wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0445] 113E. The method of embodiment 106E wherein one of the
excipients is a liquid vehicle and wherein the formulation is a
liquid formulation.
[0446] 114E. The method of embodiment 113E wherein another
excipient is a cyclodextrin
[0447] 115E. The method of embodiment 114E wherein the cyclodextrin
is sulfobutylether-13-cyclodextrin or
hydroxypropyl-13-cyclodextrin.
[0448] 116E. A method to treat an inflammation condition in a
subject comprising administering to the subject or delivering to
the subject's tissues an effective amount of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, a
formulation comprising crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one excipient or a formulation prepared from crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
one, two, three, four or more excipients.
[0449] 117E. The method of embodiment 116E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0450] 118E. The method of embodiment 116E or 117E wherein the
inflammation condition is a metabolic condition.
[0451] 119E The method of embodiment 118E wherein the metabolic
condition is type 2 diabetes.
[0452] 120E. A method to treat a autoimmune condition in a subject
comprising administering to the subject or delivering to the
subject's tissues an effective amount of crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol, a
formulation comprising crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
at least one excipient or a formulation prepared from crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol and
one, two, three, four or more excipients.
[0453] 121E. The method of embodiment 120E wherein the crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol is
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol.
[0454] 122E. The method of embodiment 120E or 121E wherein the
autoimmune condition is rheumatoid arthritis or ulcerative
colitis.
EXAMPLES
Example 1
Bulk Synthesis of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0455] 3.beta.,7.beta.-Bis-(trimethylsiloxy)-5-androsten-17-one: A
mixture of 14.87 Kg of androst-5-en-17-one-3.beta.,7.beta.-diol,
23.8 Kg HMDS and 0.7 Kg saccharin catalyst in 100 L acetonitrile
was heated to reflux for 8 hours with stirring under a nitrogen
atmosphere. Liberated ammonia was purged under slight vacuum. The
reaction volume was then reduced by distillation to collect 30 L of
distillate (requires about 2 h). The reaction volume was further
reduced to 1/2 of the original reaction volume by distillation
under reduced pressure (700 mmHg), which requires about 2 h of
heating at 50.degree. C. The resulting uniform thick slurry is
cooled to 5.degree. C. (requires about 3 h), with additional
acetonitrile added to maintain a minimum mixing volume, and held at
that temperature for 1. The precipitated product was collected by
filtration and dried at 45-50.degree. C. under vacuum (29 mmHg) to
a loss on drying (LOD) of not more than 1% (requires 20 h) to
provide 16 Kg (81% yield) of the title compound (95% purity).
[0456]
17.alpha.-Ethynyl-5-androstene-3.beta.,7.beta.,17.beta.-triol: To
11.02 Kg TMS-acetylene in 56.5 L tetrahydrofuran (THF) at
-27.degree. C. under a nitrogen atmosphere was added 8.51 L 10M
n-BuLi. The n-butyl lithium was added very slowly to maintain a
temperature at -7 to -27.degree. C. (requires about 2 h) and the
resulting reaction was stirred 10 min. at approximately 0.degree.
C. to produce TMS-lithium-acetylide. To the TMS-lithium-acetylide
solution was added a solution of 25.41 Kg of
3.beta.,7.beta.-bis-(trimethylsiloxy)-5-androsten-17-one in 95.3 L
THF filtered through a 25 .mu.m filter while allowing the reaction
temperature to rise to 20-25.degree. C. After addition was
completed, the reaction temperature was increased to 40-45.degree.
C. To quench the reactor contents, 31.8 L of methanol was added
over a period of about 1 h followed by 3.81 Kg KOH in 18.4 L giving
a final reactor temperature of 50.degree. C. Liberated acetylene is
purged under slight vacuum. The reactor contents were then
concentrated by distillation at 80.degree. C. for 1 h then under
vacuum (175 mmHg) at about 70.degree. C. (with an initial
temperature of 25.degree. C. to avoid bumping) to 1/2 of the
original pot volume. The residue was cooled to about 10.degree. C.
and 35.0 Kg of deionized water was added, followed by 16.4 Kg 12 N
HCI while maintaining a pot temperature of about 10.degree. C. and
giving a final pH of 1. Additional 26.0 kg deionized water was
added and the resulting mixture was stirred at about 5.degree. C.
for 1 h. The resulting slurry was filtered and washed with 75:25
mixture of methanol:water (16.9 L methanol, 5.6 L water). The
collected solids were dried under vacuum (28 in Hg) at 45.degree.
C. for 12 h for a loss on drying of no more than 0.5% to provide
9.6 Kg of the title compound (83% yield).
Example 2
Preparation of a Solid State Form Comprising Crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0457] A slurry of 2.1 Kg
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol in
40.2 Kg methanol, prepared from Example 1, and 4.2 Kg water in a
250 L reactor was heated to reflux with stirring until all solids
have dissolved. The reactor was cooled to 55-60.degree. C. and the
contents are pumped out into a receiving drum through a 25 micron
filter. To the reactor was transferred 2.4 Kg of methanol which was
then heated to 55-60.degree. C. The methanol rinse is the
transferred to the receiving drum as before. The contents of the
receiving drum are then transferred back into the reactor which was
fitted for vacuum distillation. The reactor contents were stirred
and heated to reflux, maintaining a pot temperature of
<=45.degree. C., under vacuum until a volume of distillate is
obtained that is equal to 1.1 to 1.5 times the volume of methanol
that had been added to the reactor prior to distillation. Deionized
water was added during the distillation to maintain the volume
necessary for stirring (20-60 Kg of water may be used). A final
solution volume in the reactor of 20-25 L was obtained. The
solution is cooled to 0-5.degree. C. and was maintained at that
temperature for at least 1 h. The reactor slurry was then filtered
through a Rosenmund filter dryer. The reactor is rinsed with 10 Kg
deionized water. The water rinse is then used to wash the filtered
product. The filter cake is dried under vacuum at 50.degree. C. for
at least 12 h whereupon a sample is tested for loss on drying.
Drying was discontinued when the loss on drying was 0.5% drying to
obtain 1.9 Kg of the titled material.
[0458] Crystalline Compound 1 (Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
(Compound 1) obtained from this procedure is represented by the low
resolution XRPD pattern (Pattern A) of FIG. 1. The peak listing for
XRPD Pattern A is provided in Table 1A.
TABLE-US-00001 TABLE 1A Peak Listing for XRPD Pattern of
Crystalline Form I Low Resolution Pattern A .degree.2.theta. d
space (.ANG.) Intensity (%) 9.65 .+-. 0.1 9.158 1.1 10.41 .+-. 0.1
8.494 25.0 12.68 .+-. 0.1 6.978 7.4 14.32 .+-. 0.1 6.179 3.6 15.12
.+-. 0.1 5.857 33.4 16.20 .+-. 0.1 5.468 53.5 16.72 .+-. 0.1 5.299
16.0 17.85 .+-. 0.1 4.966 100 18.25 .+-. 0.1 4.857 2.8 20.39 .+-.
0.1 4.351 1.3 20.91 .+-. 0.1 4.246 6.5 21.76 .+-. 0.1 4.081 1.7
22.10 .+-. 0.1 4.018 1.4 22.88 .+-. 0.1 3.884 1.0 23.95 .+-. 0.1
3.712 1.9 24.11 .+-. 0.1 3.688 2.9 24.94 .+-. 0.1 3.567 1.0 25.47
.+-. 0.1 3.495 1.7 26.10 .+-. 0.1 3.404 0.7 26.61 .+-. 0.1 3.347
2.5 27.00 .+-. 0.1 3.300 2.7 27.49 .+-. 0.1 3.242 3.6 27.98 .+-.
0.1 3.187 1.5 28.93 .+-. 0.1 3.084 7.5 29.84 .+-. 0.1 2.992 1.1
30.48 .+-. 0.1 2.931 1.5 30.81 .+-. 0.1 2.900 1.0 31.49 .+-. 0.1
2.839 2.9 32.19 .+-. 0.1 2.778 0.8 32.49 .+-. 0.1 2.754 1.4 33.70
.+-. 0.1 2.657 1.1 34.60 .+-. 0.1 2.590 0.7 34.88 .+-. 0.1 2.570
0.8 36.11 .+-. 0.1 2.486 0.5 36.48 .+-. 0.1 2.461 0.5 36.98 .+-.
0.1 2.429 0.6 37.90 .+-. 0.1 2.372 1.1 38.16 .+-. 0.1 2.356 1.6
39.05 .+-. 0.1 2.305 0.6 39.84 .+-. 0.1 2.261 3.9
Example 3
Micronization of Crystalline Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0459] Crystalline material from Example 2 was feed by vibrator
feeder into the into grinding chamber of a Jet-O-Mizer Model 0101
by Fluid Energy, Air Compressor, with air compressor output at
around 120 psi, air pressure at Pusher Nozzle and Grinding Nozzle
at approximately 110 psi 4 with a vibrator feed of -5-10 g/min.
Crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
(Compound 1) having a particle size distribution (volume weighted
average) given in Table 2 (Result-Before Micronization) is
micronized in this manner to provide crystalline Compound 1 having
particle size distribution (volume weighted distribution) given in
Table 2 (Result-After Micronization).
TABLE-US-00002 TABLE 2 Particle Size Distribution for Micronized
Crystalline Form I Compound 1 Result-Before Result-After Test Name
Micronization Micronization 90% as D(0.90) 90% is .ltoreq.331.57
micron 90% is .ltoreq.7.00 micron 95% as D(0.95) 95% is
.ltoreq.409.25 micron 95% is .ltoreq.8.47 micron 50% as D(0.50) 50%
is .ltoreq.148.84 micron 50% is .ltoreq.3.33 micron 10% as D(0.1)
10% is .ltoreq.67.45 micron 10% is .ltoreq.1.68 micron 5% as
D(0.05) 5% is .ltoreq.49.47 micron 5% is .ltoreq.1.14 micron
[0460] Crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
obtained from this procedure is represented by the low resolution
XRPD pattern of FIG. 2. The XRPD pattern of FIG. 2 is essentially
identical to the XRPD pattern of FIG. 1 (Pattern A). The peak
listing for the X-Ray Powder XRPD pattern of FIG. 2 is provided in
Table 1B.
TABLE-US-00003 TABLE 1B Peak Listing for XRPD Pattern of Micronized
Crystalline Form I High Resolution Pattern A .degree.2.theta. d
space (.ANG.) Intensity (%) 10.38 .+-. 0.1 8.520 .+-. 0.083 15
12.64 .+-. 0.1 7.004 .+-. 0.056 9 14.33 .+-. 0.1 6.182 .+-. 0.043 4
15.08 .+-. 0.1 5.876 .+-. 0.039 9 16.20 .+-. 0.1 5.472 .+-. 0.034
100 16.73 .+-. 0.1 5.303 .+-. 0.032 20 17.75 .+-. 0.1 4.996 .+-.
0.028 24 18.20 .+-. 0.1 4.873 .+-. 0.027 4 20.46 .+-. 0.1 4.351
.+-. 0.021 1 20.89 .+-. 0.1 4.258 .+-. 0.020 3 21.76 .+-. 0.1 4.084
.+-. 0.019 2 22.15 .+-. 0.1 4.017 .+-. 0.018 2 22.95 .+-. 0.1 3.886
.+-. 0.017 2 24.12 .+-. 0.1 3.690 .+-. 0.015 4 24.91 .+-. 0.1 3.575
.+-. 0.014 1 25.49 .+-. 0.1 3.497 .+-. 0.014 3 26.56 .+-. 0.1 3.358
.+-. 0.012 3 27.03 .+-. 0.1 3.303 .+-. 0.012 3 27.46 .+-. 0.1 3.246
.+-. 0.012 4 27.95 .+-. 0.1 3.195 .+-. 0.011 3 28.92 .+-. 0.1 3.088
.+-. 0.010 11 29.82 .+-. 0.1 2.996 .+-. 0.010 2
[0461] The DSC and TGA thermograms for Form I using a 10.degree.
C./min. temperature ramp are presented in FIG. 4. The DSC
thermogram show a sharp prominent endotherm at about 266.degree.
C., which is otherwise featureless. The TGA thermogram shows about
0.5% weight loss from about 30.degree. C. to about 200.degree. C.
and an additional weight loss of about 1.2% from 200.degree. C. to
250.degree. C. with significant weight loss beginning thereafter.
TG-IR analysis indicates loss of acetylene is associated with this
significant loss in weight. Melting point determination in an open
capillary shows an apparent melting point at about 256.degree. C.
Using slower san rates (e.g. 2.degree. C./min) in DSC provides
multiple endotherms some of even lower temperature. These
differences between DSC and open capillary methods may be
attributable to varying amounts of decomposition occurring
dependent on the conditions and technique used.
[0462] The peak listing for Raman absorptions in the Raman spectrum
of Form I shown in FIG. 5 is provided in Table 3.
TABLE-US-00004 TABLE 3 Peak Listing for Absorptions for Raman
Spectrum of Form I cm-1 Intensity 150.4 3.83 225.6 8.87 246.8 3.36
287.3 2.22 300.8 2.22 335.5 2.74 370.2 4.75 399.1 1.31 437.7 4.14
457.0 3.16 470.5 5.90 484.0 2.04 507.1 2.23 580.4 5.28 607.4 1.83
624.8 1.62 644.0 3.38 682.6 1.18 711.5 0.78 1.56 1.15 9.53 2.43
744.3 1.18 808.0 1.58 833.0 1.93 862.0 2.13 892.8 1.97 914.0 3.38
954.5 1.18 975.8 0.78 1004.7 1.15 1022.0 2.43 1052.9 1.18 1081.8
2.53 1099.2 1.36 1120.4 1.49 1132.0 2.64 1176.3 2.68 1195.6 3.23
1214.9 2.51 1241.9 1.22 1263.1 2.17 1297.8 2.12 1322.9 2.58 1349.9
1.89 1384.6 2.03 1436.7 6.38 1467.5 2.94 1673.9 6.07 2105.9 14.34
2842.5 5.57 2859.9 6.80 2886.9 11.19 2937.0 8.58 2946.7 7.37 2973.7
7.17 2993.0 6.75 3037.3 1.37 3280.3 1.72 3365.2 0.90
Example 4
Alternate Preparations of Solid State Forms Comprising Crystalline
Form I
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0463] A suspension of 33.37 g of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol,
prepared from Example 2, in 372 mL THF and 56 mL methanol was
heated to reflux and then allowed to cool to RT. After filtering
through Celite the filtrate was reduced in volume by 50% under
reduced pressure and then stirred for 0.5 h at ambient temperature.
The collected solids were dried under vacuum at 50.degree. C. for 2
d to give 17.72 g of the title material.
[0464] Crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
(Compound 1) obtained from this procedure is of purity .gtoreq.99%
and is represented by the low resolution XRPD pattern of FIG. 3,
which is substantially identical to the XRPD pattern in FIG. 1 or
FIG. 2. The peak listing for the XRPD pattern of FIG. 3 is provided
in Table 4.
TABLE-US-00005 TABLE 4 Peak Listing for XRPD Pattern of Crystalline
Compound 1 Obtained From An Alternate Preparation-Low Resolution
.degree.2.theta. d space (.ANG.) Intensity (%) 10.30 .+-. 0.1 8.584
10 12.54 .+-. 0.1 7.051 7 14.98 .+-. 0.1 5.917 8 16.07 .+-. 0.1
5.510 100 16.58 .+-. 0.1 5.344 18 17.63 .+-. 0.1 5.028 23 18.07
.+-. 0.1 4.906 4 20.73 .+-. 0.1 4.282 4 23.94 .+-. 0.1 3.715 6
25.33 .+-. 0.1 3.513 5 26.39 .+-. 0.1 3.374 5 26.88 .+-. 0.1 3.314
6 27.32 .+-. 0.1 3.262 8 27.80 .+-. 0.1 3.207 4 28.78 .+-. 0.1
3.100 21 32.30 .+-. 0.1 2.769 3 37.82 .+-. 0.1 2.377 4 38.06 .+-.
0.1 2.362 4 39.60 .+-. 0.1 2.274 8
[0465] Other methods to prepare crystalline Compound 1 having XRPD
patterns substantially or essentially identical to XRPD Pattern A
are given in Table 5. Crystalline material having the XRPD pattern
A with the morphology of tablets, blades, plates or needles is
referred to as Form I tablets, Form I blades, Form I plates or Form
I needles, respectively. Crystalline material prepared from Example
3 has the morphology of tablets. FIG. 6 provides optical
microscopic observations of Form I tablets and Form I needles. Form
I tablets are expected to have the advantage of favorable flow
characteristics (i.e., handling) in manufacturing. Form I needles
have expected advantages associated with particles having higher
surface to volume ratio.
TABLE-US-00006 TABLE 5 Various Other Preparation Methods for
Crystalline Compound 1 Having XRPD Pattern A and Their Morphologies
Solvent System Technique Morphology Acetone SC/FE Plates Dioxane
Slurry Undefined Dioxane SC Plates, Needles Ethanol VFE Undefined
Ethanol FE Tablets Ethanol:heptane (1:6) CP Undefined Isopropanol
Slurry Undefined Methanol Rotoevaporation Undefined Tetrahydrofuran
FE Blades out of glass Tetrahydrofuran SC/FE Plates
Tetrahydrofuran: FE Blades out of glass Ethanol (1:1)
Trifluoroethanol FE Blades
Example 5
Preparation of a Crystalline-Amorphous mixture of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0466] A ethanolic solution of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol (7.0
g in 263 mL) is sprayed dried using a Yamato spray dryer Model
Pulvis GB22 and a FMI lab pump using the following conditions:
atomizer air temp of ambient, inlet temperature of 57.degree. C.,
drying air temperature of 57.degree. C., drying air flow rate of
0.20 m.sup.2/min. and a pump setting of 0.5. The particles so
obtained are dried under vacuum at 40.degree. C. for 2-3 h to give
4.89 g of the titled material. The solid state form of Compound 1
prepared in this manner is predominately crystalline Form 1 with
about 5-10% amorphous Compound 1.
Example 6
Preparation of a solid state form comprising crystalline Form II
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0467] Substantially pure Compound 1, preferably 99% or greater
purity, as micronized Form I crystals was slurried at ambient
temperature in ethyl acetate for 9 days. The filtrate was collected
and filtered further through a 0.2 micron filter and the allowed to
evaporate at ambient temperature and pressure until crystals are
produced. Alternatively, methy ethyl ketone was used as the slurry
solvent.
[0468] Crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
obtained from this procedure is represented by the low resolution
XRPD pattern (Pattern C) of FIG. 7. The peak listing for the XRPD
pattern of FIG. 7 is provided in Table 6.
TABLE-US-00007 TABLE 6 Peak Listing for XRPD Pattern C-Low
Resolution .degree.2.theta. Intensity (%) 2.49 .+-. 0.1 10 5.04
.+-. 0.1 4 7.56 .+-. 0.1 3 10.44 .+-. 0.1 4 12.69 .+-. 0.1 4 14.43
.+-. 0.1 3 15.09 .+-. 0.1 3 16.20 .+-. 0.1 100 16.68 .+-. 0.1 4
17.73 .+-. 0.1 4 20.79 .+-. 0.1 3 21.72 .+-. 0.1 3 24.12 .+-. 0.1 3
28.92 .+-. 0.1 3
[0469] Pattern C is similar to Pattern A except for the presence of
low angle 2-theta peaks at 2.5, 5.0 and 7.6.
[0470] The DSC and TGA thermograms for this crystalline material
using a 10.degree. C./min. temperature ramp are presented in FIG.
8. The DSC thermogram shows a broad weak exotherm centered at about
207.degree. C. and a prominent sharp endotherm at about 259.degree.
C. (onset at about 246.degree. C.). The TGA thermogram shows about
1.3% weight loss from about 30.degree. C. to about 200.degree. C.
and an additional weight loss of about 2.3% from 200.degree. C. to
250.degree. C. with significant weight loss beginning thereafter.
TG-IR analysis indicates loss of acetylene is associated with this
significant loss in weight.
Example 7
Computational Determination of Form I Unit Cell Parameters
[0471] The high resolution XRPD pattern of FIG. 1B was indexed was
indexed using DASH.TM. version 3.1. The indexed solution was
verified and illustrated using CHECKCELL.TM. version Nov. 1, 2004.
FIG. 9 compares the indexed pattern of Form I with the
experimentally derived Pattern A. Agreement between the allowed
peak positions (solid lines) and the observed peaks indicates a
consistent unit cell dimension. Systematic absences due to
constructive interference of otherwise allowed peaks (dotted lines)
indicate the assigned extinction symbol is consistent with the
observed pattern. The space group [P2.sub.12.sub.12.sub.1 (#19)]
for Form I consistent with the assigned extinction symbol, unit
cell parameters and quantities derived from them are tabulated in
Table 8. Successful indexing indicates this crystalline material is
comprised primarily of a single crystalline phase.
[0472] The above indexing solution does not account for the low
angle 2-theta peak observed for the solid state form obtained from
Example 6. These reflections are consistent with reducing the
symmetry of the unit cell derived for Form I by reducing the
2.sub.1 screw of the short axis to a proper 2-fold rotation axis
and tripling this axis (i.e., three neighboring
crystallographically equivalent unit cells become non-equivalent).
The symmetry group (P2.sub.12.sub.12, #18) and unit cell parameters
obtained after these symmetry operations is provided in Table 8.
FIG. 10 compares the indexed pattern of Form II with the
experimentally derived Pattern C.
TABLE-US-00008 TABLE 8 Indexing Solutions and Derived Quantities
Form Form I Form II Family and Orthorhombic Orthorhombic Space
Group P2.sub.12.sub.12.sub.1 (#19) P2.sub.12.sub.12 (#18) Z'/Z 1/4
3/12 a (.ANG.) 11.740 12.273 b (.ANG.) 12.273 12.339 c (.ANG.)
12.339 35.220 .alpha. (deg) 90 90 .beta. (deg) 90 90 .gamma. (deg)
90 90 Volume (.ANG..sup.3/cell) 1777.9 5333.6 V/Z
(.ANG..sup.3/asym. unit) 444.5 Assumed Composition.sup.a
C.sub.21H.sub.30O.sub.3 Density (g/cm.sup.3).sup.a 1.24 Weight
Fraction N/A Solvent (%).sup.a XRPD File 329880 331226
Example 8
Preparation of a solid state form comprising crystalline Form III
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0473] Form III was prepared by crash precipitation of an ethanolic
solution of substantially pure Compound 1 at ambient temperature by
adding water to the solution to provide a EtOH:water solvent ratio
of 1:8.
[0474] Crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
obtained from this procedure is represented by the low resolution
XRPD pattern (Pattern B) of FIG. 11. The peak listing for the XRPD
pattern of FIG. 11 is provided in Table 9.
TABLE-US-00009 TABLE 9 Peak Listing for XRPD Pattern B-Low
Resolution .degree.2.theta. d space (.ANG.) Intensity (%) 7.41 .+-.
0.1 11.979 .+-. 0.164 2 8.34 .+-. 0.1 10.602 .+-. 0.128 1 10.23
.+-. 0.1 8.622 .+-. 0.085 3 12.27 .+-. 0.1 7.214 .+-. 0.059 4 14.67
.+-. 0.1 6.038 .+-. 0.041 3 15.24 .+-. 0.1 5.814 .+-. 0.038 54
15.66 .+-. 0.1 5.659 .+-. 0.036 100 16.59 .+-. 0.1 5.344 .+-. 0.032
32 18.21 .+-. 0.1 4.872 .+-. 0.027 5 18.54 .+-. 0.1 4.786 .+-.
0.026 3 19.32 .+-. 0.1 4.601 .+-. 0.024 3 20.04 .+-. 0.1 4.431 .+-.
0.022 5 20.37 .+-. 0.1 4.360 .+-. 0.021 3 21.87 .+-. 0.1 4.064 .+-.
0.018 3 22.11 .+-. 0.1 4.021 .+-. 0.018 5 22.77 .+-. 0.1 3.905 .+-.
0.017 3 23.10 .+-. 0.1 3.855 .+-. 0.017 3 24.18 .+-. 0.1 3.681 .+-.
0.015 5 24.42 .+-. 0.1 3.650 .+-. 0.015 4 24.69 .+-. 0.1 3.610 .+-.
0.014 5 25.11 .+-. 0.1 3.551 .+-. 0.014 6 25.65 .+-. 0.1 3.481 .+-.
0.013 4 25.86 .+-. 0.1 3.445 .+-. 0.013 4 26.19 .+-. 0.1 3.403 .+-.
0.013 3 26.73 .+-. 0.1 3.335 .+-. 0.012 3 27.75 .+-. 0.1 3.215 .+-.
0.011 11
[0475] The DSC and TGA thermograms for this crystalline material
using a 10.degree. C./min. temperature ramp are presented in FIG.
12 The DSC thermogram shows a prominent sharp endotherm at about
266.degree. C. (onset at about 258.degree. C.), an additional
endotherm at about 1.7.degree. C. (onset at about -4.16.degree. C.)
and a broad endotherm centered at about 105.degree. C. Associated
with the lower two DSC endotherms is about 9.6% weight loss in TGA
from about 20.degree. C. to about 110.degree. C. TG-IR analysis
indicates water loss is associated with this loss in weight. These
results are consistent with a pseudopolymorph that is a
dihydrate
[0476] The peak listing for Raman absorptions in the Raman spectrum
of FIG. 13 of this crystalline material is shown is given in Table
10.
TABLE-US-00010 TABLE 10 Peak Listing for Raman Absorptions for a
Solid State Form Comprising Crystalline Form III cm-1 Intensity
146.5 2.52 223.6 1.94 250.6 1.53 293.1 0.73 335.5 1.12 379.8 1.09
401.1 0.37 435.8 1.54 457.0 1.20 516.8 1.10 580.4 1.19 605.5 0.51
619.0 0.45 653.7 0.48 680.7 3.55 711.5 0.54 744.3 0.90 809.9 0.43
862.0 0.41 875.5 0.50 894.7 0.87 914.0 0.39 952.6 0.50 970.0 0.66
983.5 0.63 1008.5 1.03 1027.8 0.55 1049.0 0.81 1068.3 0.63 1081.8
0.55 1105.0 0.79 1118.5 0.71 1133.9 0.89 1160.9 0.44 1182.1 0.85
1195.6 0.64 1226.5 0.59 1251.5 0.93 1278.5 0.57 1299.7 0.64 1319.0
0.95 1344.1 0.79 1380.7 0.51 1436.7 1.78 1469.4 0.99 1666.1 1.43
2107.8 2.88 2832.9 0.79 2854.1 1.26 2892.7 1.14 2933.2 2.41 2950.5
1.67 2966.0 1.94 2985.2 1.36 3029.6 0.31 3272.6 0.36
Example 9
Preparation of a solid state form comprising crystalline Form IV
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0477] Form IV was prepared by dissolving about 24 mg substantially
pure Compound 1 in about 1 mL 1:1 chloroform:methanol and filtering
the solution through a 0.2 micron filter. The solution was then
allowed to evaporate under ambient temperature and pressure until
solids formed.
[0478] Crystalline
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
obtained from this procedure is represented by the low resolution
XRPD pattern of FIG. 14. The peak listing for the XRPD pattern of
FIG. 14 is provided in Table 11.
TABLE-US-00011 TABLE 11 Peak Listing for XRPD Pattern of Form IV
.degree.2.theta. Intensity (%) 7.44 .+-. 0.1 2.6 8.31 .+-. 0.1 3.1
10.44 .+-. 0.1 2.7 12.27 .+-. 0.1 2.7 15.24 .+-. 0.1 67 15.66 .+-.
0.1 100 16.20 .+-. 0.1 3.2 16.62 .+-. 0.1 69 17.85 .+-. 0.1 2.3
18.21 .+-. 0.1 2.5 18.51 .+-. 0.1 2.3 19.32 .+-. 0.1 2.3 20.04 .+-.
0.1 2.6 20.43 .+-. 0.1 2.5 22.11 .+-. 0.1 2.5 22.86 .+-. 0.1 2.2
23.22 .+-. 0.1 2.2 24.48 .+-. 0.1 2.3 24.69 .+-. 0.1 2.6 25.08 .+-.
0.1 2.6 25.56 .+-. 0.1 2.3 25.92 .+-. 0.1 2.3 26.22 .+-. 0.1 2.2
26.73 .+-. 0.1 1.9 27.75 .+-. 0.1 2.5 30.15 .+-. 0.1 1.7 31.32 .+-.
0.1 1.8 32.25 .+-. 0.1 1.8 34.47 .+-. 0.1 1.6 37.74 .+-. 0.1
1.6
[0479] The DSC and TGA thermograms for this crystalline material
using a 10.degree. C./min. temperature ramp are presented in FIG.
15. The DSC thermogram shows a prominent sharp endotherm at about
266.degree. C. (onset at about 257.degree. C.), an additional
endotherm at about 79.degree. C. (onset at about 75.degree. C.) or
88.degree. C. (onset at about 84.degree. C.) and an overlapping
broad endotherm centered at about 98.degree. C. Associated with the
lower two DSC endotherms is about 9.7% weight loss in TGA from
about 20.degree. C. to about 110.degree. C. These results are
consistent with a pseudopolymorph comprising Compound 1 and
methanol.
[0480] The peak listing for Raman absorptions in the Raman spectrum
of FIG. 16 of this crystalline material is shown is given in Table
12.
TABLE-US-00012 TABLE 12 Peak Listing for Raman Absorptions for a
Solid State Form Comprising Crystalline Form IV cm-1 Intensity
146.5 1.82 223.6 1.52 291.1 0.54 335.5 0.78 377.9 0.79 435.8 1.12
457.0 0.92 466.6 0.80 516.8 0.77 580.4 0.99 605.5 0.42 622.8 0.38
653.7 0.38 680.7 2.81 711.5 0.43 744.3 0.71 808.0 0.34 877.4 0.41
894.7 0.75 914.0 0.32 952.6 0.45 970.0 0.55 983.5 0.50 1008.5 0.82
1027.8 0.47 1049.0 0.68 1068.3 0.52 1081.8 0.46 1105.0 0.65 1118.5
0.56 1133.9 0.71 1180.2 0.69 1195.6 0.56 1226.5 0.49 1251.5 0.80
1276.6 0.50 1299.7 0.57 1319.0 0.75 1344.1 0.63 1380.7 0.40 1436.7
1.43 1469.4 0.76 1666.1 1.10 2107.8 2.81 2832.9 0.85 2858.0 1.41
2890.7 1.28 2933.2 2.39 2950.5 1.72 2966.0 1.92 2985.2 1.36 3029.6
0.33 3270.7 0.26
Example 10
Preparation of amorphous
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0481] Amorphous Compound 1 was prepared by first heating a mixture
of 150 mg Compound 1 in 11 mL t-butanol at 45.degree. C. and then
filtering the solution to remove residual solids. The solution was
then lyophilized to provide the title material. XRPD analysis shows
a broad band centered at about 16 2-theta degrees with no
distinctive peaks as shown in FIG. 17 consistent for amorphous
material.
[0482] The modulated DSC thermogram, using a temperature ramp of
1.degree. C./min., in FIG. 18 shows a reversing heat flow trace
(middle DSC trace) that provides a glass transition temperature
(T.sub.g) of 44.degree. C. when measured at the inflection point of
the trace. The upper DSC trace in this Figure shows the
non-reversing heat flow and the lower DSC trace is the total heat
flow. TGA, using a 10.degree. C./min. temperature ramp, also in
FIG. 18, shows a weight loss of about 11.5% from about 30.degree.
C. to about 110.degree. C. and an additional weight loss of about
5% between about 110.degree. C. and about 200.degree. C. with
significant weight loss thereafter. Brief thermal stress of a
sample of amorphous Compound 1 at 40.degree. C. resulted in
crystalline material that contains Form I.
[0483] The peak listing for Raman absorptions in the Raman spectrum
of FIG. 19 of amorphous material is given in Table 13.
TABLE-US-00013 TABLE 13 Peak Listing for Raman Absorptions for
Amorphous Compound 1 cm-1 Intensity 146.5 0.52 225.6 0.99 331.6
0.34 372.1 0.50 435.8 0.47 470.5 0.62 484.0 0.32 512.9 0.32 538.0
0.20 580.4 0.67 607.4 0.32 622.8 0.26 684.5 1.08 711.5 0.23 748.2
0.73 808.0 0.18 833.0 0.15 862.0 0.22 894.7 0.38 914.0 0.26 973.8
0.29 1006.6 0.37 1052.9 0.32 1103.0 0.31 1120.4 0.37 1174.4 0.42
1199.5 0.34 1251.5 0.30 1301.7 0.30 1326.7 0.32 1384.6 0.26 1438.6
0.95 1673.9 0.55 2105.8 1.15 2858.0 1.03 2888.8 1.02 2937.0 1.45
2971.7 1.22
Example 11
Formulations comprising or prepared from a solid state form of
17.alpha.-ethynyl-androst-5-ene-3.beta.,7.beta.,17.beta.-triol
[0484] The following are example ingredient lists used in
preparation of formulations containing Compound 1 in a solid state
form (e.g., Form I) that are suitable for oral dosing.
TABLE-US-00014 TABLE 14 Formulation Containing 25 mg Compound 1 in
Solid State Form % w/w mg/capsule Drug Substance Compound 1
micronized 10 25 Excipients Sodium lauryl sulfate, NF 20 50
Microcrystalline cellulose, NF 43.2 108 (Avicel PH 102)
Crospovidone, NF (Polypasdone XL-10) 26 65 Magnesium stearate, NF
0.8 2 Total 100 250 Hard gelatin capsule # 1
TABLE-US-00015 TABLE 15 Formulation Containing 5 mg Compound 1 in
Solid State Form % w/w mg/capsule Drug Substance Compound 1
micronized 3.3 5 Excipients Sodium lauryl sulfate, NF 16.7 25
Microcrystalline cellulose, NF 49.3 74 (Avicel PH 102)
Crospovidone, NF (Polypasdone XL-10) 30.0 45 Magnesium stearate, NF
0.7 1 Total 100 150 Hard gelatin capsule # 2
[0485] The following is an example ingredient list used in
preparation of a suspension formulation of Compound 1 in a solid
state form (e.g., Form I) suitable for oral or parenteral
dosing.
TABLE-US-00016 TABLE 16 Suspension Formulation Containing Compound
1 in Solid State Form w/v or % w/v Drug Substance Compound 1
micronized 3 mg/mL Excipients Polysorbate 80 2 Sodium
Carboxymethycellulose 0.1 Sodium Chloride 0.9 Phenol 0.05 Deionized
water
[0486] Suspension formulations of at least up to 100 mg/mL may be
prepared using the formulation of Table 16. In the formulations
above and in the following examples solid state forms of Compound 1
(e.g., amorphous or crystalline Form I) are preferably micronized
to a mean volume weighted particle size (Dv, 50) of between about 3
to about 100 microns prior to blending with excipients. In one
embodiment, Crystalline Form I is micronized to give a particle
size with (Dv, 90)<10 .mu.m (particle size that contains 90%
(volume weighted) of all the particles). Selection of appropriate
particle size is a tradeoff between improved bioavailability for a
solid state form of Compound 1 in a given formulation due to
improved dissolution rate of solid state Compound 1 and increased
manufacturing cost of the formulation as particle size decreases.
For example, particle sizes with a mean volume weighted particle
size or average diameter of less than about 3 microns typically
requires fluid bed micronization [for example, see Julia Z. H, et
al. "Fluid bed granulation of a poorly water soluble, low density,
micronized drug: comparison with high shear granulation" Int. J.
Pharm. Vol. 237, No. 1-2, pp. 1-14 (2002)], which is more costly
than jet milling to a larger particle size and is a process more
difficult to scale up.
[0487] With dosage strengths of less than 5 mg (e.g., 1 mg)
pre-blending of micronized Compound 1 with a surface active agent
such as sodium lauryl sulfate is sometimes conducted prior to
blending with the remaining excipients in order to obtain a uniform
distribution of Compound 1 within the formulation.
* * * * *